Predictive Oncology (POAI) S-4 25 Mar 16 2015 FY Registration of securities issued in business combination transactions Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 16, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Skyline Medical Inc.
Trading Symbol	skln
Document Type	S4
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		49,894,145
Entity Public Float			$ 5,873,239
Amendment Flag	false
Entity Central Index Key	1,446,159
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current Assets:
Cash	$ 4,856,232	$ 16,384
Accounts Receivable	38,283	57,549
Inventories	231,740	367,367
Prepaid Expense and other assets	271,579	190,015
Total Current Assets	5,397,834	631,315
Fixed Assets, net	139,598	196,479
Intangibles, net	94,987	73,183
Total Assets	5,632,419	900,977
Current Liabilities:
Accounts Payable	650,413	2,194,518
Accrued Expenses	864,295	3,066,379
Short-term notes payable net of discounts of $0 and $194,097 (See Note 4)		937,424
Deferred Revenue	5,000	5,000
Total Current Liabilities	$ 1,519,708	6,203,321
Accrued Expenses		$ 213,883
Liability for equity-linked financial instruments (See Note 8)
Total Liabilities	$ 1,519,708	$ 6,417,204
Commitments and Contingencies
Stockholders’ Equity (Deficit):
Common Stock, $.01 par value, 100,000,000 authorized, 5,206,428 and 3,092,766 outstanding	$ 52,063	$ 30,927
Additional paid-in capital	44,534,135	30,093,745
Accumulated deficit	(40,492,437)	(35,641,105)
Total Stockholders' Equity (Deficit)	4,112,711	(5,516,227)
Total Liabilities and Stockholders' Equity (Deficit)	5,632,419	900,977
Series A Convertible Preferred Stock [Member]
Stockholders’ Equity (Deficit):
Convertible Preferred Stock		$ 206
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity (Deficit):
Convertible Preferred Stock	$ 18,950

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Discount on short-term notes payable (in Dollars)	$ 0	$ 194,097
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares outstanding	5,206,428	3,092,766
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, stated value (in Dollars per share)	$ 100	$ 100
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	20,550
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	1,895,010	0

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenue	$ 654,354	$ 951,559
Cost of goods sold	303,982	385,323
Gross margin	350,372	566,236
General and administrative expense	3,399,339	4,882,549
Operations expense	846,687	972,830
Sales and marketing expense	503,989	1,178,305
Interest expense	390,887	377,719
Loss (gain) on valuation of equity-linked financial instruments		(11,599)
Total Expense	5,140,902	7,399,804
Net loss available to common shareholders	$ (4,790,530)	$ (6,833,568)
Loss per common share - basic and diluted (in Dollars per share)	$ (1.23)	$ (2.29)
Weighted average shares used in computation - basic and diluted (in Shares)	3,880,828	2,990,471

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficit) - USD ($)	Note Conversion at $6.68 Per Share [Member]Common Stock [Member]	Note Conversion at $6.68 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $6.68 Per Share [Member]	Note Conversion at $6.68 Per Share 2 [Member]Common Stock [Member]	Note Conversion at $6.68 Per Share 2 [Member]Additional Paid-in Capital [Member]	Note Conversion at $6.68 Per Share 2 [Member]	Note Conversion at $5.85 Per Share [Member]Common Stock [Member]	Note Conversion at $5.85 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $5.85 Per Share [Member]	Note Conversion at $5.03 Per Share [Member]Common Stock [Member]	Note Conversion at $5.03 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $5.03 Per Share [Member]	Note Conversion at $5.14 Per Share [Member]Common Stock [Member]	Note Conversion at $5.14 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $5.14 Per Share [Member]	Note Conversion at $5.00 Per Share [Member]Common Stock [Member]	Note Conversion at $5.00 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $5.00 Per Share [Member]	Note Conversion at $5.26 Per Share [Member]Common Stock [Member]	Note Conversion at $5.26 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $5.26 Per Share [Member]	Note Conversion at $5.26 Per Share 2 [Member]Common Stock [Member]	Note Conversion at $5.26 Per Share 2 [Member]Additional Paid-in Capital [Member]	Note Conversion at $5.26 Per Share 2 [Member]	Note Conversion at $5.95 Per Share [Member]Common Stock [Member]	Note Conversion at $5.95 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $5.95 Per Share [Member]	Note Conversion at $5.05 Per Share [Member]Common Stock [Member]	Note Conversion at $5.05 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $5.05 Per Share [Member]	Note Conversion at $2.90 Per Share [Member]Common Stock [Member]	Note Conversion at $2.90 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $2.90 Per Share [Member]	Note Conversion at $2.96 Per Share [Member]Common Stock [Member]	Note Conversion at $2.96 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $2.96 Per Share [Member]	Note Conversion at $2.91 Per Share [Member]Common Stock [Member]	Note Conversion at $2.91 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $2.91 Per Share [Member]	Note Conversion at $2.77 Per Share [Member]Common Stock [Member]	Note Conversion at $2.77 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $2.77 Per Share [Member]	Note Conversion at $2.25 Per Share [Member]Common Stock [Member]	Note Conversion at $2.25 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $2.25 Per Share [Member]	Note Conversion at $2.00 Per Share [Member]Common Stock [Member]	Note Conversion at $2.00 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $2.00 Per Share [Member]	Note Conversion at $2.27283 Per Share [Member]Common Stock [Member]	Note Conversion at $2.27283 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $2.27283 Per Share [Member]	Note Conversion at $2.0179 Per Share [Member]Common Stock [Member]	Note Conversion at $2.0179 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $2.0179 Per Share [Member]	Note Conversion at $2.00 Per Share 2 [Member]Common Stock [Member]	Note Conversion at $2.00 Per Share 2 [Member]Additional Paid-in Capital [Member]	Note Conversion at $2.00 Per Share 2 [Member]	Note Conversion at $1.92417 Per Share [Member]Common Stock [Member]	Note Conversion at $1.92417 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $1.92417 Per Share [Member]	Note Conversion at $1.8578 Per Share [Member]Common Stock [Member]	Note Conversion at $1.8578 Per Share [Member]Additional Paid-in Capital [Member]	Note Conversion at $1.8578 Per Share [Member]	Series A Convertible Preferred Stock [Member]Common Stock [Member]Shares Issued at $19.50 Per Share [Member]	Series A Convertible Preferred Stock [Member]Common Stock [Member]Shares Issued at $19.50 Per Share 2 [Member]	Series A Convertible Preferred Stock [Member]Common Stock [Member]Shares Issued at $19.50 Per Share 3 [Member]	Series A Convertible Preferred Stock [Member]Common Stock [Member]Shares Issued at $19.50 Per Share 4 [Member]	Series A Convertible Preferred Stock [Member]Common Stock [Member]Shares Issued at $9.75 Per Share [Member]	Series A Convertible Preferred Stock [Member]Common Stock [Member]Shares Issued at $9.75 Per Share 2 [Member]	Series A Convertible Preferred Stock [Member]Common Stock [Member]Shares Issued at $9.75 Per Share 3 [Member]	Series A Convertible Preferred Stock [Member]Additional Paid-in Capital [Member]Shares Issued at $19.50 Per Share [Member]	Series A Convertible Preferred Stock [Member]Additional Paid-in Capital [Member]Shares Issued at $19.50 Per Share 2 [Member]	Series A Convertible Preferred Stock [Member]Additional Paid-in Capital [Member]Shares Issued at $19.50 Per Share 3 [Member]	Series A Convertible Preferred Stock [Member]Additional Paid-in Capital [Member]Shares Issued at $19.50 Per Share 4 [Member]	Series A Convertible Preferred Stock [Member]Additional Paid-in Capital [Member]Shares Issued at $9.75 Per Share [Member]	Series A Convertible Preferred Stock [Member]Additional Paid-in Capital [Member]Shares Issued at $9.75 Per Share 2 [Member]	Series A Convertible Preferred Stock [Member]Additional Paid-in Capital [Member]Shares Issued at $9.75 Per Share 3 [Member]	Series A Convertible Preferred Stock [Member]Retained Earnings [Member]Shares Issued at $19.50 Per Share [Member]	Series A Convertible Preferred Stock [Member]Retained Earnings [Member]Shares Issued at $19.50 Per Share 2 [Member]	Series A Convertible Preferred Stock [Member]Retained Earnings [Member]Shares Issued at $19.50 Per Share 3 [Member]	Series A Convertible Preferred Stock [Member]Retained Earnings [Member]Shares Issued at $19.50 Per Share 4 [Member]	Series A Convertible Preferred Stock [Member]Retained Earnings [Member]Shares Issued at $9.75 Per Share 2 [Member]	Series A Convertible Preferred Stock [Member]Retained Earnings [Member]Shares Issued at $9.75 Per Share 3 [Member]	Series A Convertible Preferred Stock [Member]Shares Issued at $19.50 Per Share 4 [Member]	Series A Convertible Preferred Stock [Member]Shares Issued at $9.75 Per Share 2 [Member]	Series A Convertible Preferred Stock [Member]Shares Issued at $9.75 Per Share 3 [Member]	Preferred Stock [Member]	Common Stock [Member]Warrant Exercisable at $15.00 Per Share [Member]	Common Stock [Member]Option Exercisable at $1.25 Per Share [Member]	Common Stock [Member]Shares Issued at $20.63 Per Share [Member]	Common Stock [Member]Warrant Exercisable at $12.75 Per Share [Member]	Common Stock [Member]Option Exercisable at $5.25 Per Share [Member]	Common Stock [Member]Warrant Exercisable at $0.75 Per Share [Member]	Common Stock [Member]Warrant Exercisable at $13.50 Per Share [Member]	Common Stock [Member]Shares Issued at $18.75 Per Share [Member]	Common Stock [Member]Warrant Exercisable at $7.50 Per Share [Member]	Common Stock [Member]Warrant Exercisable at $5.63 Per Share [Member]	Common Stock [Member]Warrant Exercisable at $12.75 Per Share 2 [Member]	Common Stock [Member]Warrant Exercisable at $11.25 Per Share [Member]	Common Stock [Member]Shares Issued at $11.25 Per Share [Member]	Common Stock [Member]Shares Issued at $18.75 Per Share 2 [Member]	Common Stock [Member]Warrant Exercisable at $13.50 Per Share 2 [Member]	Common Stock [Member]Warrant Exercisable at $9.75 Per Share [Member]	Common Stock [Member]Warrant Exercisable at $5.63 Per Share 2 [Member]	Common Stock [Member]Option Exercisable at $5.25 Per Share 2 [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Warrant Exercisable at $15.00 Per Share [Member]	Additional Paid-in Capital [Member]Option Exercisable at $1.25 Per Share [Member]	Additional Paid-in Capital [Member]Shares Issued at $20.63 Per Share [Member]	Additional Paid-in Capital [Member]Warrant Exercisable at $12.75 Per Share [Member]	Additional Paid-in Capital [Member]Option Exercisable at $5.25 Per Share [Member]	Additional Paid-in Capital [Member]Warrant Exercisable at $0.75 Per Share [Member]	Additional Paid-in Capital [Member]Warrant Exercisable at $13.50 Per Share [Member]	Additional Paid-in Capital [Member]Shares Issued at $18.75 Per Share [Member]	Additional Paid-in Capital [Member]Warrant Exercisable at $7.50 Per Share [Member]	Additional Paid-in Capital [Member]Warrant Exercisable at $5.63 Per Share [Member]	Additional Paid-in Capital [Member]Warrant Exercisable at $12.75 Per Share 2 [Member]	Additional Paid-in Capital [Member]Warrant Exercisable at $11.25 Per Share [Member]	Additional Paid-in Capital [Member]Shares Issued at $11.25 Per Share [Member]	Additional Paid-in Capital [Member]Shares Issued at $18.75 Per Share 2 [Member]	Additional Paid-in Capital [Member]Warrant Exercisable at $13.50 Per Share 2 [Member]	Additional Paid-in Capital [Member]Warrant Exercisable at $9.75 Per Share [Member]	Additional Paid-in Capital [Member]Warrant Exercisable at $5.63 Per Share 2 [Member]	Additional Paid-in Capital [Member]Option Exercisable at $5.25 Per Share 2 [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Warrant Exercisable at $15.00 Per Share [Member]	Option Exercisable at $1.25 Per Share [Member]	Shares Issued at $20.63 Per Share [Member]	Warrant Exercisable at $12.75 Per Share [Member]	Option Exercisable at $5.25 Per Share [Member]	Warrant Exercisable at $0.75 Per Share [Member]	Warrant Exercisable at $13.50 Per Share [Member]	Shares Issued at $18.75 Per Share [Member]	Warrant Exercisable at $7.50 Per Share [Member]	Warrant Exercisable at $5.63 Per Share [Member]	Warrant Exercisable at $12.75 Per Share 2 [Member]	Warrant Exercisable at $11.25 Per Share [Member]	Shares Issued at $11.25 Per Share [Member]	Shares Issued at $18.75 Per Share 2 [Member]	Warrant Exercisable at $13.50 Per Share 2 [Member]	Warrant Exercisable at $9.75 Per Share [Member]	Warrant Exercisable at $5.63 Per Share 2 [Member]	Option Exercisable at $5.25 Per Share 2 [Member]	Total
Balance at Dec. 31, 2013																																																																																																										$ 29,325																			$ 25,449,636	$ (28,697,415)																			$ (3,218,454)
Balance (in Shares) at Dec. 31, 2013																																																																																																										2,932,501
Shares issued for warrant exercise																																																																																								$ 17			$ 33		$ 22	$ 27		$ 48	$ 31	$ 3	$ 78			$ 37	$ 14	$ 111			$ 1,279			$ 2,460		$ 1,608	$ 35,973		$ 3,557	$ 2,302	$ 221	$ 52,422			$ 2,757	$ 1,044	$ 62,389				$ 1,296			$ 2,493		$ 1,630	$ 36,000		$ 3,605	$ 2,333	$ 224	$ 52,500			$ 2,794	$ 1,058	$ 62,500
Shares issued for warrant exercise (in Shares)																																																																																								1,728			3,323		2,174	2,667		4,807	3,112	299	7,778			3,725	1,410	11,111
Shares issued																																																																																							$ 206																																						2,054,795																				2,055,001
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares																																																																$ 10	$ 16	$ 16	$ 16				$ 18,909	$ 30,384	$ 30,385	$ 30,385				$ (18,919)	$ (30,400)	$ (30,401)	$ (30,402)			$ (1)
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares (in Shares)																																																																972	1,561	1,561	1,561
Shares adjusted for rounding per reverse stock split																																																																																																										$ 1																			1																				2
Shares adjusted for rounding per reverse stock split (in Shares)																																																																																																										106
Net loss																																																																																																																														(6,833,568)																			(6,833,568)
Value of equity instruments issued with debt																																																																																																																													313,175																				313,175
Vesting Expense																																																																																																																													705,434																				705,434
Options issued as part of employee bonus																																																																																																																													694,500																				694,500
Shares issued for option exercise																																																																																									$ 43			$ 3													$ 3			$ 5,387			$ 1,397													$ 1,747				$ 5,430			$ 1,400													$ 1,750
Shares issued for option exercise (in Shares)																																																																																									4,336			267													333
Shares issued for a note conversion	$ 30	$ 19,970	$ 20,000	$ 30	$ 19,970	$ 20,000	$ 34	$ 19,966	$ 20,000	$ 38	$ 19,962	$ 20,000	$ 39	$ 19,961	$ 20,000	$ 40	$ 19,960	$ 20,000	$ 38	$ 19,962	$ 20,000	$ 57	$ 29,943	$ 30,000	$ 50	$ 29,950	$ 30,000	$ 556	$ 280,060	$ 280,616
Shares issued for a note conversion (in Shares)	3,018			3,019			3,435			3,894			3,894			3,997			3,804			5,706			5,044			55,568
Shares issued into an escrow account per settlement agreement																																																																																																										$ 137																																							137
Shares issued into an escrow account per settlement agreement (in Shares)																																																																																																										13,700
Shares issued as Investor Relations compensation																																																																																										$ 20					$ 13					$ 21	$ 13								$ 41,230					$ 24,987					$ 23,979	$ 24,987									$ 41,250					$ 25,000					$ 24,000	$ 25,000
Shares issued as Investor Relations compensation (in Shares)																																																																																										2,000					1,333					2,133	1,333
Reduction in escrow account per settlement agreement																																																																																																										$ (44)																			(3,289)																				(3,333)
Reduction in escrow account per settlement agreement (in Shares)																																																																																																										(4,444)
Balance at Dec. 31, 2014																																																																																							206																			$ 30,927																			30,093,745	(35,641,105)																			(5,516,227)
Balance (in Shares) at Dec. 31, 2014																																																																																																										3,092,766
Shares issued for warrant exercise																																																																																																										$ 30																			9,870																				9,900
Shares issued for warrant exercise (in Shares)																																																																																																										3,000
Shares issued																																																																																							16,667																			$ 16,667																			13,027,546																				13,060,880
Shares issued (in Shares)																																																																																																										1,666,667
Preferred stock conversion																																																																																							2,077																			$ 2,283																			(4,360)																				0
Preferred stock conversion (in Shares)																																																																																																										228,343
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares																																																																				$ 31	$ 31	$ 31					$ (31)	$ 30,369	$ 30,371					$ (30,401)	$ (30,401)		$ (1)	$ 1
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares (in Shares)																																																																				3,122	3,121	3,121
Net loss																																																																																																																														(4,790,530)																			(4,790,530)
Vesting Expense																																																																																																																													871,877																				871,877
Shares issued for a note conversion																															$ 34	$ 9,966	$ 10,000	$ 68	$ 19,932	$ 20,000	$ 103	$ 29,897	$ 30,000	$ 120	$ 33,358	$ 33,478	$ 156	$ 34,844	$ 35,000	$ 200	$ 39,800	$ 40,000	$ 880	$ 199,120	$ 200,000	$ 149	$ 29,851	$ 30,000	$ 150	$ 29,850	$ 30,000	$ 130	$ 24,870	$ 25,000	$ 162	$ 29,838	$ 30,000
Shares issued for a note conversion (in Shares)																															3,447			6,762			10,313			12,098			15,552			20,000			87,997			14,867			15,000			12,993			16,148
Reduction in escrow account per settlement agreement																																																																																																										$ (89)																			(6,578)																				(6,667)
Reduction in escrow account per settlement agreement (in Shares)																																																																																																										(8,889)
Balance at Dec. 31, 2015																																																																																							$ 18,950																			$ 52,063																			$ 44,534,135	$ (40,492,437)																			$ 4,112,711
Balance (in Shares) at Dec. 31, 2015																																																																																																										5,206,428

Statements of Stockholders' Eq6

Statements of Stockholders' Equity (Deficit) (Parentheticals)	12 Months Ended
	Dec. 31, 2015$ / shares	Dec. 31, 2014$ / shares
Warrant exercise price
Common Stock [Member] | Warrant Exercisable at $15.00 Per Share [Member]
Warrant exercise price		$ 15
Common Stock [Member] | Option Exercisable at $1.25 Per Share [Member]
Option exercise price		1.25
Common Stock [Member] | Shares Issued at $20.63 Per Share [Member]
Investor Relations compensation		20.63
Common Stock [Member] | Warrant Exercisable at $12.75 Per Share [Member]
Warrant exercise price		12.75
Common Stock [Member] | Option Exercisable at $5.25 Per Share [Member]
Option exercise price		5.25
Common Stock [Member] | Warrant Exercisable at $0.75 Per Share [Member]
Warrant exercise price		0.75
Common Stock [Member] | Warrant Exercisable at $13.50 Per Share [Member]
Warrant exercise price		13.50
Common Stock [Member] | Shares Issued at $18.75 Per Share [Member]
Investor Relations compensation		18.75
Common Stock [Member] | Warrant Exercisable at $7.50 Per Share [Member]
Warrant exercise price		7.50
Common Stock [Member] | Warrant Exercisable at $5.63 Per Share [Member]
Warrant exercise price		5.63
Common Stock [Member] | Warrant Exercisable at $12.75 Per Share 2 [Member]
Warrant exercise price		12.75
Common Stock [Member] | Warrant Exercisable at $11.25 Per Share [Member]
Warrant exercise price		11.25
Common Stock [Member] | Shares Issued at $11.25 Per Share [Member]
Investor Relations compensation		11.25
Common Stock [Member] | Shares Issued at $18.75 Per Share 2 [Member]
Investor Relations compensation		18.75
Common Stock [Member] | Warrant Exercisable at $13.50 Per Share 2 [Member]
Warrant exercise price		13.50
Common Stock [Member] | Warrant Exercisable at $9.75 Per Share [Member]
Warrant exercise price		9.75
Common Stock [Member] | Warrant Exercisable at $5.63 Per Share 2 [Member]
Warrant exercise price		5.63
Common Stock [Member] | Option Exercisable at $5.25 Per Share 2 [Member]
Option exercise price		$ 5.25
Series A Convertible Preferred Stock [Member] | Shares Issued at $19.50 Per Share [Member]
Number of shareholders		16
Series A Convertible Preferred Stock [Member] | Shares Issued at $19.50 Per Share 2 [Member]
Number of shareholders		16
Series A Convertible Preferred Stock [Member] | Shares Issued at $19.50 Per Share 3 [Member]
Number of shareholders		16
Series A Convertible Preferred Stock [Member] | Shares Issued at $19.50 Per Share 4 [Member]
Number of shareholders		16
Series A Convertible Preferred Stock [Member] | Shares Issued at $9.75 Per Share [Member]
Number of shareholders	16
Series A Convertible Preferred Stock [Member] | Shares Issued at $9.75 Per Share 2 [Member]
Number of shareholders	16
Series A Convertible Preferred Stock [Member] | Shares Issued at $9.75 Per Share 3 [Member]
Number of shareholders	16
Series A Convertible Preferred Stock [Member] | Common Stock [Member] | Shares Issued at $19.50 Per Share [Member]
Series A Convertible Preferred Stock Dividends		$ 19.50
Series A Convertible Preferred Stock [Member] | Common Stock [Member] | Shares Issued at $19.50 Per Share 2 [Member]
Series A Convertible Preferred Stock Dividends		19.50
Series A Convertible Preferred Stock [Member] | Common Stock [Member] | Shares Issued at $19.50 Per Share 3 [Member]
Series A Convertible Preferred Stock Dividends		19.50
Series A Convertible Preferred Stock [Member] | Common Stock [Member] | Shares Issued at $19.50 Per Share 4 [Member]
Series A Convertible Preferred Stock Dividends		19.50
Series A Convertible Preferred Stock [Member] | Common Stock [Member] | Shares Issued at $9.75 Per Share [Member]
Series A Convertible Preferred Stock Dividends	$ 9.75
Series A Convertible Preferred Stock [Member] | Common Stock [Member] | Shares Issued at $9.75 Per Share 2 [Member]
Series A Convertible Preferred Stock Dividends	9.75
Series A Convertible Preferred Stock [Member] | Common Stock [Member] | Shares Issued at $9.75 Per Share 3 [Member]
Series A Convertible Preferred Stock Dividends	9.75
Note Conversion at $6.68 Per Share [Member] | Common Stock [Member]
Note conversion price		6.68
Note Conversion at $6.68 Per Share 2 [Member] | Common Stock [Member]
Note conversion price		6.68
Note Conversion at $5.85 Per Share [Member] | Common Stock [Member]
Note conversion price		5.85
Note Conversion at $5.03 Per Share [Member] | Common Stock [Member]
Note conversion price		5.03
Note Conversion at $5.14 Per Share [Member] | Common Stock [Member]
Note conversion price		5.14
Note Conversion at $5.00 Per Share [Member] | Common Stock [Member]
Note conversion price		5
Note Conversion at $5.26 Per Share [Member] | Common Stock [Member]
Note conversion price		5.26
Note Conversion at $5.26 Per Share 2 [Member] | Common Stock [Member]
Note conversion price		5.26
Note Conversion at $5.95 Per Share [Member] | Common Stock [Member]
Note conversion price		5.95
Note Conversion at $5.05 Per Share [Member] | Common Stock [Member]
Note conversion price		$ 5.05
Note Conversion at $2.90 Per Share [Member] | Common Stock [Member]
Note conversion price	2.90
Note Conversion at $2.96 Per Share [Member] | Common Stock [Member]
Note conversion price	2.96
Note Conversion at $2.91 Per Share [Member] | Common Stock [Member]
Note conversion price	2.91
Note Conversion at $2.77 Per Share [Member] | Common Stock [Member]
Note conversion price	2.77
Note Conversion at $2.25 Per Share [Member] | Common Stock [Member]
Note conversion price	2.25
Note Conversion at $2.00 Per Share [Member] | Common Stock [Member]
Note conversion price	2
Note Conversion at $2.27283 Per Share [Member] | Common Stock [Member]
Note conversion price	2.27283
Note Conversion at $2.0179 Per Share [Member] | Common Stock [Member]
Note conversion price	2.0179
Note Conversion at $2.00 Per Share 2 [Member] | Common Stock [Member]
Note conversion price	2
Note Conversion at $1.92417 Per Share [Member] | Common Stock [Member]
Note conversion price	1.92417
Note Conversion at $1.8578 Per Share [Member] | Common Stock [Member]
Note conversion price	$ 1.8578

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flow from operating activities:
Net loss	$ (4,790,530)	$ (6,833,568)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	78,566	63,040
Vested stock options and warrants	871,877	723,367
Equity instruments issued for management and consulting	(6,667)	112,054
Amortization of debt discount	219,097	247,338
Penalty on debt provision	10,031
Loss on Sales of Equipment	17,076
(Gain) loss on valuation of equity-linked instruments		(11,599)
Changes in assets and liabilities:
Accounts receivable	19,266	39,696
Inventories	135,627	(245,192)
Prepaid expense and other assets	(81,564)	(129,427)
Accounts payable	(1,544,105)	1,132,410
Accrued expenses	(2,415,967)	1,594,468
Deferred Revenue		(64,000)
Net cash used in operating activities:	(7,487,293)	(3,371,413)
Cash flow from investing activities:
Purchase of fixed assets	(32,470)	(101,409)
Purchase of intangibles	(28,095)	(19,828)
Net cash used in investing activities	(60,565)	(121,237)
Cash flow from financing activities:
Proceeds from long-term and convertible debt	250,000	1,500,000
Principal payments on debt	(933,074)	(305,000)
Net proceeds from issuance of preferred stock	18,950	2,055,000
Net proceeds from issuance of common stock	13,051,830	157,081
Net cash provided by financing activities	12,387,706	3,407,081
Net increase (decrease) in cash	4,839,848	(85,569)
Cash at beginning of period	16,384	101,953
Cash at end of period	4,856,232	16,384
Non cash transactions:
Common stock issued for accrued interest/bonus		694,500
Common stock issued to satisfy debt	$ 483,478	$ 480,616

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations and Continuance of Operations Skyline Medical Inc. (the "Company") was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. As of December 31, 2015, the registrant had 5,206,428 shares of common stock, par value $.01 per share, outstanding, adjusted for a 1-for-75 reverse stock split effective October 24, 2014. In this Report, all numbers of shares and per share amounts, as appropriate, have been stated to reflect the reverse stock split. Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY FMS products. The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 whereupon the Company closed its public offering of units of common stock, Series B Convertible Preferred Stock and Series A Warrants (the “Units”). There remains though, substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Since inception to December 31, 2015, the Company raised approximately $22,732,961 in equity, inclusive of $2,055,000 from a private placement of Series A Convertible Preferred Stock, $13,555,003 from the public offering of Units and $5,685,000 in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources.” Recent Accounting Developments In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers In June 2014, the FASB issued ASU 2014-12, "Compensation - Stock Compensation" In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued ASU No. 2015-11 , Inventory (Topic 330): Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU 2015-17, “Income Taxes (Topic 740)” We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations. Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 — Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management’s best estimate of the related risks and return at the time the impairment assessment is made. Accounting Policies and Estimates The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. Advertising Advertising costs are expensed as incurred. Advertising expenses were $8,220 in 2015, and $19,394 in 2014. Research and Development Research and development costs are charged to operations as incurred. Research and development costs were approximately $261,000 and $394,000 for 2015 and 2014, respectively. Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605- Revenue Recognition. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution kits may be returned. Additionally, since the Company buys both the STREAMWAY FMS units and cleaning solution kits from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur. Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements. Inventories Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: December 31, December 31, Finished goods $ 30,237 $ 88,362 Raw materials 162,623 237,556 Work-In-Process 38,880 41,449 Total $ 231,740 $ 367,367 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: December 31, December 31, Computers and office equipment $ 153,553 $ 123,708 Leasehold Improvements 23,874 23,874 Manufacturing Tooling 97,288 97,288 Demo Equipment 8,962 30,576 Total 283,677 275,446 Less: Accumulated Depreciation 144,079 78,967 Total Fixed Assets, Net $ 139,598 $ 196,479 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Intangible Assets Intangible assets consist of trademarks and patent costs. These assets are not subject to amortization until the property patented is in production. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified. Income Taxes The Company accounts for income taxes in accordance with ASC 740- Income Taxes (“ASC 740”) The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. Tax years subsequent to 2012 remain open to examination by federal and state tax authorities. Patents and Intellectual Property On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired. Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and U.S. Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023. In July 2015, Skyline Medical filed an international (PCT) patent application for its fluid waste collection system and received a favorable determination by the International Searching Authority finding that all of the claims satisfy the requirements for novelty, inventive step and industrial applicability. Skyline anticipates that the favorable International Search Report will result in allowance of its various national applications. Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one financial institution. The Company had a credit risk concentration as a result of depositing $4,621,764 of funds in excess of insurance limits in a single bank. Product Warranty Costs In 2015, the Company incurred approximately $56,201 in current warranty costs. Segments The Company operates in one segment for the sale of its medical device and consumable products. Substantially all of the Company’s assets, revenues, and expenses for 2015 and 2014 were located at or derived from operations in the United States. There were no revenues from sales outside of the United States. Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.

Note 2 _ Development Stage Oper

Note 2 – Development Stage Operations	12 Months Ended
	Dec. 31, 2015
Development Stage Enterprise Disclosures [Abstract]
Development Stage Enterprise Disclosures [Text Block]	NOTE 2 – DEVELOPMENT STAGE OPERATIONS The Company was formed April 23, 2002. Since inception through December 31, 2015, 5,206,428 shares of common stock have been issued between par value and $125.25. Operations since incorporation have primarily been devoted to raising capital, obtaining financing, development of the Company’s product, administrative services, customer acceptance and sales and marketing strategies.

Note 3 _ Stockholders_ Equity (

Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 3 – STOCKHOLDERS’ EQUITY (DEFICIT), STOCK OPTIONS AND WARRANTS Public Offering of Units On August 31, 2015 (the “Issuance Date”), the Company completed a public offering (the “Offering”) of 1,666,667 Units (the “Units”) as described below. The public offering price in the Offering was $9.00 per Unit, and the purchase price for the underwriter of the Offering (the “Underwriter”) was $8.28 per Unit, resulting in an underwriting discount and commission of $0.72 (or 8.00%) per Unit and total net proceeds to the Company before expenses of $13.8 million. The Company had granted the Underwriter an option for a period of 45 days to purchase up to an additional 250,000 Units solely to cover over-allotments. The Underwriter chose not to purchase any additional Units under the over-allotment option. The Company paid to the Underwriter a non-accountable expense allowance equal to 1% of the gross proceeds of the Offering and agreed to reimburse expenses incurred by the Underwriter up to $70,000. On August 31, 2015, as a result of the communication of the Offering and the issuance of the 228,343 Exchange Units in the Unit Exchange described below, the Company issued a total of 1,895,010 Units, comprised of a total of aggregate of 1,895,010 shares of Common Stock, 1,895,010 shares of Series B Preferred Stock and 7,580,040 Series A Warrants. Each Unit consisted of one share of common stock, par value $0.01 per share (the “Common Stock”), one share of Series B Convertible Preferred Stock (“Series B Preferred Stock”) and four Series A Warrants. The shares of Common Stock, the shares of Series B Preferred Stock and the Series A Warrants that comprise the Units automatically separated on February 29, 2016. For a description of the terms of the Series B Convertible Preferred Stock included within the Units, see “Certificate of Designation for Series B Preferred Stock” below. For a description of the terms of the Series A Warrants included within the Units, see “Series A Warrants” below. Series A Warrants Holders may exercise Series A Warrants by paying the exercise price in cash or, in lieu of payment of the exercise price in cash, by electing to receive a number of shares of Common Stock equal to the Black Scholes Value (as defined below) based upon the number of shares the holder elects to exercise. The number of shares of Common Stock to be delivered will be determined according to the following formula, referred to as the “Cashless Exercise.” Total Shares = (A x B) / C Where: · Total Shares is the number of shares of Common Stock to be issued upon a Cashless Exercise. · A is the total number of shares with respect to which the Series A Warrant is then being exercised. · B is the Black Scholes Value (as defined below). · C is the closing bid price of the Common Stock as of two trading days prior to the time of such exercise, provided that in no event may “C” be less than $0.43 per share (subject to appropriate adjustment in the event of stock dividends, stock splits or similar events affecting the Common Stock). The Black Scholes Value (as defined above) as of March 11, 2016 was $4.3246, and the closing bid price of Common Stock as of March 11, 2016, was $0.18. Therefore, an exercise on that date would have resulted in the issuance of 10.06 shares of Common Stock for each Series A Warrant. Approximately 3,390,935 Series A Warrants have been exercised in cashless exercises as of March 11, 2016, resulting in the issuance of 34,053,653 shares of Common Stock. If all of the remaining 4,189,105 Series A Warrants that were issued as part of the Units sold in the Offering and part of the Units issued on August 31, 2015 were exercised pursuant to a cashless exercise and the closing bid price of our common stock as of the two trading days prior to the time of such exercise was $0.43 per share or less and the Black Scholes Value were $4.3246 (the Black Scholes Value as of March 11, 2016), then a total of approximately 42,130,704 shares of our common stock would be issued to the holders of such Series A Warrants. The potential for such dilutive exercise of the Series A Warrants may depress the price of our common stock regardless of the Company’s business performance, and could encourage short selling by market participants, especially if the trading price of our common stock begins to decrease. The Series A Warrants will not be exercisable or exchangeable by the holder of such warrants to the extent (and only to the extent) that the holder or any of its affiliates would beneficially own in excess of 4.99% of the common stock of the Company, determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the regulations promulgated thereunder. In addition to (but not duplicative of) the adjustments to the exercise price and the number of shares of Common Stock issuable upon exercise of the Series A Warrants in the event of stock dividends, stock splits, reorganizations or similar events, the Series A Warrants provide for certain adjustments if the Company, at any time prior to the three year anniversary of the Issuance Date, (1) declares or makes any dividend or other distribution of its assets (or rights to acquire its assets) to all or substantially all of the holders of shares of Common Stock at any time after the Issuance Date, or (2) grants, issues or sells any options, convertible securities or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of shares of Common Stock. Further, if at any time a Series A Warrant is outstanding, the Company consummates any fundamental transaction, as described in the Series A Warrants and generally including any consolidation or merger into another corporation, or the sale of all or substantially all of our assets, or other transaction in which the Common Stock is converted into or exchanged for other securities or other consideration, the holder of any Series A Warrants will thereafter receive, the securities or other consideration to which a holder or the number of shares of Common Stock then deliverable upon the exercise or exchange of such Series A Warrants would have been entitled upon such consolidation or merger or other transaction. Unit Purchase Option. Series B Preferred Stock. Unit Exchange. Redemption of Convertible Notes. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options under this plan have terms ranging from three to ten years. Accounting for share-based payment The Company has adopted ASC 718- Compensation-Stock Compensation ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. Since the Company's common stock has no significant public trading history, and the Company has experienced no significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of 2 to 7 years of 15 small-cap medical companies traded on major exchanges and 10 mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter. When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first-hand experience with how its investors and consultants have acted in similar circumstances, the assumptions the Company uses in calculating the fair value of stock-based payment awards represent its best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based consulting and interest expense could be materially different in the future. Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. In January 2014 the Company issued 4,336 shares of common stock to the former CEO at $1.25 per share upon his exercising options. In January through March 2014, 9 warrant holders exercised warrants through a cashless exercise for a total of 15,442 shares of common stock. In January and February 2014 the Company issued warrants to purchase 21,538 shares pursuant to a February 4, 2014 private placement whereby the Company issued 20,550 shares of Series A Convertible Preferred Stock raising gross proceeds of $2,055,000. The warrants are at an exercise price of $24.38. In February 2014 the Company issued a warrant to purchase 1,482 shares of common stock at an exercise price of $20.25 to a major shareholder Dr. Samuel Herschkowitz. The warrant is in consideration for a bridge loan extended in December 2013 that has been paid in February 2014. On March 31, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $19.50 per share. As a result 970 shares of common stock were issued to 16 holders of Preferred Shares. In March 2014, the Company issued 4,444 shares of common stock to a warrant holder for a partial cash exercise at $11.25 per share; issued 3,333 shares to the holder via the cashless exercise of the remainder of the warrant. In June 2014, the Company issued 3,725 shares of common stock to a warrant holder exercising cashless warrants. On June 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $19.50 per share. As a result 1,561 shares of common stock were issued to 16 holders of Preferred Shares. On June 30, 2014, the Company issued a warrant to purchase 5,431 shares of common stock at an exercise price of $12.38 to SOK Partners, LLC, in consideration for a bridge loan in the form of convertible notes. On September 9, 2014 the Resale Registration Statement went into effect. The convertible note agreement provided an immediate approximately 11% reduction to the warrant agreement. Therefore, the warrant has been adjusted to purchase 4,831 shares of common stock at an exercise price of $12.38 to SOK Partners, LLC in consideration for a bridge loan. In July 2014, the Company issued warrants to purchase 28,986 shares of common stock at an exercise price of $12.38 to two lenders in consideration for a bridge loan in the form of convertible notes. The shares above reflect approximately an 11% reduction resulting from the Resale Registration Statement that went effective September 9, 2014. In August 2014, the Company issued warrants to purchase 61,539 of common stock at an exercise price of $24.38 to the Purchasers of the Preferred Shares. The Securities Purchase Agreement with the Preferred Shareholders stipulated that if the Company was not listed on either the NASDAQ Stock Market, the New York Stock Exchange or the NYSE MKT within 180 days of closing the agreement then warrants to purchase the above additional shares would be issued in aggregate to the Preferred Shareholders. In August and September 2014, the Company issued warrants to purchase 37,440 shares of common stock at an exercise price of $12.38 to four lenders in consideration for a bridge loan in the form of convertible notes. The shares above reflect the approximate 11% reduction resulting from the Resale Registration Statement that went effective September 9, 2014. On September 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $19.50 per share. As a result 1,561 shares of common stock were issued to 16 holders of Preferred Shares. In November 2014, the Company issued 13,700 shares of common stock, par value $0.01, in escrow for debt settlement. On December 31, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $19.50 per share. As a result 1,559 shares of common stock were issued to 16 holders of Preferred Shares. For grants of stock options and warrants in 2014 the Company used a 1.44% to 2.75% risk-free interest rate, 0% dividend rate, 59% or 66% volatility and estimated terms of 5 or 10 years. Value computed using these assumptions ranged from $3.2006 to $13.9195 per share. In January 2015, the Company issued a dividend adjustment to the Purchasers of the Preferred Shares as described above. Certain previous dividends paid were calculated with an exercise price of $19.50 per share, but should have been calculated at $9.75 per share. As a result 3,122 shares of common stock were issued to 16 holders of Preferred Shares. On March 31, 2015, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $9.75 per share. As a result 3,121 shares of common stock were issued to 16 holders of Preferred Shares. On June 30, 2015, the Company issued dividends to Purchases of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $9.75 per share. As a result 3,121 shares of common stock were issued to 16 holders of Preferred Shares. For grants of stock options and warrants in 2015 the Company used a 1.63% to 2.35% risk-free interest rate, 0% dividend rate, 59% to 66% volatility and estimated terms of 5 to 10 years. Value computed using these assumptions ranged from $0.2750 to $5.5695 per share. The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Average Average Outstanding at December 31, 2013 385,733 $ 6.75 461,920 $ 10.50 Issued 75,683 8.12 161,375 3.81 Expired (7,879 ) 23.58 (81,851 ) 13.54 Exercised (4,936 ) 1.76 (40,722 ) 8.38 Outstanding at December 31, 2014 448,601 $ 7.51 500,722 $ 7.95 Issued 354,253 2.76 7,581,722 4.95 Cancelled (19,136 ) 11.73 (1,967 ) 11.34 Exercised - - (3,000 ) 4.95 Outstanding at December 31, 2015 783,718 $ 5.33 8,077,477 $ 5.14 At December 31, 2015, 780,718 stock options are fully vested and currently exercisable with a weighted average exercise price of $5.29 and a weighted average remaining term of 8.17 years. There are 8,077,477 warrants that are fully vested and exercisable. Stock-based compensation recognized in 2015 and 2014 was $871,877 and $723,367, respectively. The Company has $32,682 of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next 2 months. The following summarizes the status of options and warrants outstanding at December 31, 2015: Range of Exercise Prices Shares Weighted Options: $0.75 7,333 5.52 $2.63 250,481 9.81 $2.94 30,614 10.01 $3.10 59,681 9.50 $3.21 6,232 9.76 $3.45 7,245 9.25 $4.875 134 7.20 $5.25 2,031 6.69 $5.625 192,000 7.21 $5.925 23,206 7.22 $6.00 123,998 6.63 $6.50 3,845 9.01 $8.25 3,636 8.76 $9.9375 3,019 7.54 $10.50 3,238 7.54 $11.25 13,666 7.09 $12.75 67 7.36 $13.875 2,160 8.25 $71.25 40,261 8.19 $18.75 3,334 8.15 $20.25 4,940 8.01 $21.75 1,336 7.77 $23.85 1,260 7.75 Total 783,718 Warrants: $4.95 7,577,040 4.67 $6.00 102,857 2.20 $9.00 2,666 2.07 $9.75 63,227 3.59 $11.25 203,801 2.02 $12.375 71,257 3.61 $12.38 5,557 3.85 $13.50 4,444 2.47 $14.85 23,612 2.41 $20.25 1,481 3.13 $24.375 21,535 3.10 Total 8,077,477 Stock options and warrants expire on various dates from June 2017 to December 2025. On July 24, 2015, an amendment to the Certificate of Incorporation became effective, pursuant to which the authorized common stock was increased to 100,000,000 shares of common stock and the authorized preferred stock was increased to 20,000,000 shares. Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of December 31, 2015 by year of grant: Year Shares Price 2011 11,666 .75 2012 126,029 5.25 – 6.00 2013 232,756 4.875 – 23.85 2014 59,013 6.50 – 18.75 2015 354,253 2.63 – 3.45 Total 783,718 $ .75 – 23.85 Warrants: Year Shares Price 2012 69,801 11.25 – 15.00 2013 267,579 6.00 – 14.85 2014 161,375 12.375 – 24.375 2015 7,578,722 4.95 Total 8,077,477 $ 4.95 – 24.375

Note 4 - Short-term Notes Payab

Note 4 - Short-term Notes Payable	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block [Abstract]
Short-term Debt [Text Block]	NOTE 4 – SHORT-TERM NOTES PAYABLE From July through September 2014, we entered into a series of securities purchase agreements pursuant to which we issued approximately $1.8 million original principal amount (subsequently reduced to approximately $1.6 million aggregate principal amount in accordance with their terms) of convertible promissory notes (the “2014 Convertible Notes”) and warrants exercisable for shares of our common stock for an aggregate purchase price of $1,475,000. Of this amount, we issued to SOK Partners, LLC, an affiliate of the Company, $122,196 original principal amount of the 2014 Convertible Notes and warrants exercisable for 5,431 shares of our common stock for an aggregate purchase price of $100,000. In April and May 2015, we issued and sold to a private investor additional Convertible Notes in an aggregate original principal amount of $275,000 for an aggregate purchase price of $250,000, containing terms substantially similar to the 2014 Convertible Notes (the “2015 Convertible Notes” and, together with the 2014 Convertible Notes, the “Convertible Notes”). No warrants were issued with the 2015 Convertible Notes. Under a provision in the existing agreements, upon effectiveness of a resale registration statement covering certain shares, on September 9, 2014, the principal amount of the notes was reduced by 11%, to $1,603,260 and the number of Warrants was reduced by 11%, to 71,257 shares. As of June 30, 2015, $927,663 aggregate principal amount of Convertible Notes, plus accrued and unpaid interest thereto, have been converted into shares of our common stock and $933,073 aggregate principal amount of Convertible Notes remained outstanding. In connection with the Offering, the holders of the Convertible Notes agreed to not exercise their right to convert the Convertible Notes into shares of the Company’s common stock, in exchange for the Company’s agreement to redeem all of the outstanding Convertible Notes promptly following the consummation of the Offering at a redemption price equal to 140% of the principal amount, plus accrued and unpaid interest to the redemption date. On August 31, 2015, the closing date of the offering, the Company redeemed the remaining $933,074 aggregate principal amount of Convertible Notes plus interest and a 40% redeemable premium, for a total payment of $1,548,792. Of this amount, approximately $167,031 was paid to its affiliates in redemption of their Convertible Notes. Each holder of the Convertible Notes agreed to the foregoing terms and entered into an Amendment to Senior Convertible Notes and Agreement with the Company. As of December 31, 2015 none of the Convertible Notes were outstanding.

Note 5 - Loss Per Share

Note 5 - Loss Per Share	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	NOTE 5 - LOSS PER SHARE The following table presents the shares used in the basic and diluted loss per common share computations: Year Ended 2015 2014 Numerator: Net loss available in basic and diluted calculation $ (4,790,530 ) $ (6,833,568 ) Denominator: Weighted average common shares outstanding-basic 3,880,828 2,990,471 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-diluted 3,880,828 2,990,471 Loss per common share-basic and diluted $ (1.23 ) $ (2.29 ) (1) The number of shares underlying options and warrants outstanding as of December 31, 2015 and December 31, 2014 are 8,861,195 and 949,323, respectively. The number of shares underlying the preferred stock as of December 31, 2015 is 1,898,010. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 6 - Income Taxes

Note 6 - Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 6– INCOME TAXES The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. There is no income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a 100% valuation allowance for the deferred tax assets and state income taxes is appropriate. During September 2013, the Company experienced an "ownership change" as defined in Section 382 of the Internal Revenue Code which could potentially limit the ability to utilize the Company’s net operating losses (NOLs). The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change. At December 31, 2014, the Company had approximately $18.7 million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2015, subject to the Section 382 limitation described above. The federal NOLs will expire beginning in 2022 if unused. The Company also had approximately $12.4 million of gross NOLs to reduce future state taxable income at December 31, 2014, which will expire in years 2022 through 2034 if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At December 31, 2014, the federal and state valuation allowances were $8.1 million and $1.0 million, respectively. At December 31, 2015, the Company had approximately $24.7 million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2016, subject to the Section 382 limitation described above. The federal NOLs will expire beginning in 2022 if unused. The Company also had approximately $13.4 million of gross NOLs to reduce future state taxable income at December 31, 2015, which will expire in years 2022 through 2035 if unused. The Company’s net deferred tax assets, which include the NOLs are subject to a full valuation allowance. At December 31, 2015, the federal and state valuation allowances were $9.6 million and $1.1 million, respectively. The valuation allowance has been recorded due to the uncertainty of realization of the benefits associated with the net operating losses. Future events and changes in circumstances could cause this valuation allowance to change. The components of deferred income taxes at December 31, 2015 and December 31, 2014 are as follows: December 31, December 31, Deferred Tax Asset: Net Operating Loss $ 10,338,000 $ 7,919,000 Other 359,000 1,150,000 Total Deferred Tax Asset 10,697,000 9,069,000 Less Valuation Allowance 10,697,000 9,069,000 Net Deferred Income Taxes $ — $ —

Note 7 _ Rent Obligation

Note 7 – Rent Obligation	12 Months Ended
	Dec. 31, 2015
Leases [Abstract]
Leases of Lessee Disclosure [Text Block]	NOTE 7 – RENT OBLIGATION The Company leases its principal office under a lease that can be cancelled after three years with proper notice per the lease and an amortized schedule of adjustments that will be due to the landlord. The lease extends five years and expires January 2018. In addition to rent, the Company pays real estate taxes and repairs and maintenance on the leased property. Rent expense was $66,345 and $64,753 for 2015 and 2014, respectively. The Company’s rent obligation for the next three years are as follows: 2016 $ 38,000 2017 $ 39,000 2018 $ 3,000

Note 8 _ Liability for Equity-L

Note 8 – Liability for Equity-Linked Financial Instruments	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 8 – LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS The Company adopted ASC 815- Derivatives and Hedging (“ASC 815”) on January 1, 2009. ASC 815 mandates a two-step process for evaluating whether an equity-linked financial instrument or embedded feature is indexed to the entity's own stock. It was effective for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years, which was the Company's first quarter of 2009. Many of the warrants issued by the Company contain a strike price adjustment feature, which upon adoption of ASC 815, changed the classification (from equity to liability) and the related accounting for warrants with a $479,910 estimated fair value of as of January 1, 2009. An adjustment was made to remove $486,564 from paid-in capital (the cumulative values of the warrants on their grant dates), a positive adjustment of $6,654 was made to accumulated deficit, representing the gain on valuation from the grant date to January 1, 2009, and $479,910 was booked as a liability. The warrants issued in 2011 do not contain a strike price adjustment feature and, therefore, are not treated as a liability. The January 1, 2009 valuation was computed using the Black-Scholes valuation model based upon a 2.5-year expected term, an expected volatility of 63%, an exercise price of $34.50 per share, a stock price of $26.25, a zero dividend rate and a 1.37% risk free interest rate. Subsequent to January 1, 2009 these warrants were re-valued at the end of each quarter and a gain or loss was recorded based upon their increase or decrease in value during the quarter. Likewise, new warrants that were issued during 2009 and 2010 were valued, using the Black- Scholes valuation model on their date of grant and an entry was made to reduce paid-in capital and increase the liability for equity-linked financial instruments. These warrants were also re-valued at the end of each quarter based upon their expected life, the stock price, the exercise price, assumed dividend rate, expected volatility and risk free interest rate. A significant reduction in the liability was realized in 2010 primarily due to a reduction from $37.50 to $16.50 per share in the underlying stock price. The Company realized a slight increase in the liability for existing warrants during the first quarter of 2012. In 2013 there was a significant decrease in the liability primarily due to current expirations and the amount of warrants reaching expiration in the near term. In 2014, all warrants expired and the liability was reduced to zero. The inputs to the Black-Scholes model during 2009 through 2014 were as follows: Stock price $3.75 to $37.50 Exercise price $ .75 to $24.38 Expected life (years) 2.0 to 6.5 Expected volatility 59% Assumed dividend rate - % Risk-free interest rate .13% to 2.97% The original valuations, annual gain (loss) and end of year valuations are shown below: Initial Value Annual Gain (Loss) Value at 12/31/09 2010 Gain (Loss) Value at 12/31/10 2011 Gain (Loss) Value at 2012 Gain Value 2013 Gain Value 2014 Gain Value at January 1, 2009 adoption $ 479,910 $ (390,368 ) $ 870,278 $ 868,772 $ 1,506 $ (88,290 ) $ 89,796 $ (21,856 ) $ 111,652 $ 100,053 $ 11,599 $ 11,599 $ - Warrants issued in quarter ended 6/30/2009 169,854 20,847 149,007 147,403 1,604 (4,689 ) 6,293 6,293 - - - - - Warrants issued in quarter ended 9/30/2009 39,743 (738 ) 40,481 40,419 62 (1,562 ) 1,624 910 714 714 - - - Warrants is used in quarter ended 12/31/2009 12,698 617 12,081 12,053 28 (724 ) 752 415 337 337 - - - Subtotal 702,205 1,071,847 Warrants issued in quarter ended 3/31/2010 25,553 25,014 539 (5,570 ) 6,109 3,701 2,408 2,408 - - - Warrants issued in quarter ended 6/30/2010 31,332 30,740 592 (6,122 ) 6,714 6,083 631 631 - - - Warrants issued in quarter ended 9/30/2010 31,506 20,891 10,615 (44,160 ) 54,775 1,338 53,437 53,437 - - - Total $ 790,596 $ (369,642 ) $ 1,071,847 $ 1,145,292 $ 14,946 $ (151,117 ) $ 166,063 $ (3,116 ) $ 169,179 $ 157,580 $ 11,599 $ 11,599 $ -

Note 9 - Related Pary Transacti

Note 9 - Related Pary Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 9 - RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. Rick Koenigsberger, a director, is a holder of membership units in SOK Partners. In connection with the sale of the Series A Preferred Shares on February 4, 2014, Joshua Kornberg, our President, Chief Executive Officer and Interim Chairman of the Board, was one of the purchasers. Mr. Kornberg purchased 19,231 Series A Preferred Shares for a purchase price of $25,000 and received warrants to purchase 52 shares of common stock. SOK Partners, LLC (“SOK”), a 10% stockholder with Mr. Kornberg and Dr. Samuel Herschkowitz as managing partners, invested in the July 2014 offering of convertible notes and warrants. In November 2014, the convertible noteholders agreed to convert certain balances of the convertible notes in connection with the public offering of the Existing Units, in consideration of the agreement to issue certain additional shares. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources – History Financing – 2014 Sales of Convertible Notes and Warrants.” In connection with the Unit Offering in August 2015, all such convertible notes were redeemed at a redemption price of 140% of the principal amount thereof, plus accrued and unpaid interest. The Company paid approximately $163,000 to SOK in redemption of its convertible note. In addition, Ricardo Koenigsberger, a former director who resigned on June 5, 2015, is a holder of membership units of SOK Partners. In connection with the Unit Exchange that was consummated on August 31, 2015, 250 shares of Series A Convertible Stock held by Mr. Kornberg were exchanged for 2,778 Exchange Units.

Note 10 - Retirement Savings Pl

Note 10 - Retirement Savings Plans	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 10 – RETIREMENT SAVINGS PLANS We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2014, and again in 2015, we matched 100%, of the employee’s contribution up to 4.0% of their earnings. The employer contribution was $39,916 and $37,730 in 2015 and 2014. There were no discretionary contributions to the plan in 2015 and 2014.

Note 11 - Supplemental Cash Flo

Note 11 - Supplemental Cash Flow Data	12 Months Ended
	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	NOTE 11 – SUPPLEMENTAL CASH FLOW DATA Cash payments for interest were $246,620 and $47,111 for the fiscal years ended December 31, 2015 and December 31, 2014, respectively.

Note 12 - Subsequent Events

Note 12 - Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 12 – SUBSEQUENT EVENTS In January 2016 we commenced a registered offer (the “Exchange Offer”) to exchange, on a one-for-one basis, new units (the “New Units”) in exchange for the 1,895,010 outstanding units (the “Existing Units”) that were issued in the Offering and the Unit Exchange. Each New Unit, if issued, would have consisted of shares of common stock and certain warrants to purchase common stock. On March 2, 2016, we announced the termination of the Exchange Offer. None of the Existing Units were accepted for exchange in the Exchange Offer.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Skyline Medical Inc. (the "Company") was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. As of December 31, 2015, the registrant had 5,206,428 shares of common stock, par value $.01 per share, outstanding, adjusted for a 1-for-75 reverse stock split effective October 24, 2014. In this Report, all numbers of shares and per share amounts, as appropriate, have been stated to reflect the reverse stock split. Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY FMS products. The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 whereupon the Company closed its public offering of units of common stock, Series B Convertible Preferred Stock and Series A Warrants (the “Units”). There remains though, substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Since inception to December 31, 2015, the Company raised approximately $22,732,961 in equity, inclusive of $2,055,000 from a private placement of Series A Convertible Preferred Stock, $13,555,003 from the public offering of Units and $5,685,000 in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources.”
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Developments In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers In June 2014, the FASB issued ASU 2014-12, "Compensation - Stock Compensation" In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs In July 2015, the FASB issued ASU No. 2015-11 , Inventory (Topic 330): Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU 2015-17, “Income Taxes (Topic 740)” We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations. Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 — Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management’s best estimate of the related risks and return at the time the impairment assessment is made. Accounting Policies and Estimates The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. Advertising Advertising costs are expensed as incurred. Advertising expenses were $8,220 in 2015, and $19,394 in 2014. Research and Development Research and development costs are charged to operations as incurred. Research and development costs were approximately $261,000 and $394,000 for 2015 and 2014, respectively. Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605- Revenue Recognition. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution kits may be returned. Additionally, since the Company buys both the STREAMWAY FMS units and cleaning solution kits from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur. Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements. Inventories Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: December 31, December 31, Finished goods $ 30,237 $ 88,362 Raw materials 162,623 237,556 Work-In-Process 38,880 41,449 Total $ 231,740 $ 367,367 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: December 31, December 31, Computers and office equipment $ 153,553 $ 123,708 Leasehold Improvements 23,874 23,874 Manufacturing Tooling 97,288 97,288 Demo Equipment 8,962 30,576 Total 283,677 275,446 Less: Accumulated Depreciation 144,079 78,967 Total Fixed Assets, Net $ 139,598 $ 196,479 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Intangible Assets Intangible assets consist of trademarks and patent costs. These assets are not subject to amortization until the property patented is in production. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified. Income Taxes The Company accounts for income taxes in accordance with ASC 740- Income Taxes (“ASC 740”) The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. Tax years subsequent to 2012 remain open to examination by federal and state tax authorities. Patents and Intellectual Property On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired. Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and U.S. Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023. In July 2015, Skyline Medical filed an international (PCT) patent application for its fluid waste collection system and received a favorable determination by the International Searching Authority finding that all of the claims satisfy the requirements for novelty, inventive step and industrial applicability. Skyline anticipates that the favorable International Search Report will result in allowance of its various national applications. Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one financial institution. The Company had a credit risk concentration as a result of depositing $4,621,764 of funds in excess of insurance limits in a single bank.
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]	Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 — Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management’s best estimate of the related risks and return at the time the impairment assessment is made.
Use of Estimates, Policy [Policy Text Block]	Accounting Policies and Estimates The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Presentation of Taxes Collected from Customers Policy [Policy Text Block]	Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations.
Advertising Costs, Policy [Policy Text Block]	Advertising Advertising costs are expensed as incurred. Advertising expenses were $8,220 in 2015, and $19,394 in 2014.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development costs were approximately $261,000 and $394,000 for 2015 and 2014, respectively.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605- Revenue Recognition. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution kits may be returned. Additionally, since the Company buys both the STREAMWAY FMS units and cleaning solution kits from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur.
Receivables, Policy [Policy Text Block]	Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: December 31, December 31, Finished goods $ 30,237 $ 88,362 Raw materials 162,623 237,556 Work-In-Process 38,880 41,449 Total $ 231,740 $ 367,367
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: December 31, December 31, Computers and office equipment $ 153,553 $ 123,708 Leasehold Improvements 23,874 23,874 Manufacturing Tooling 97,288 97,288 Demo Equipment 8,962 30,576 Total 283,677 275,446 Less: Accumulated Depreciation 144,079 78,967 Total Fixed Assets, Net $ 139,598 $ 196,479 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Intangible assets consist of trademarks and patent costs. These assets are not subject to amortization until the property patented is in production. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740- Income Taxes (“ASC 740”) The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. Tax years subsequent to 2012 remain open to examination by federal and state tax authorities.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents and Intellectual Property On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired. Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and U.S. Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023. In July 2015, Skyline Medical filed an international (PCT) patent application for its fluid waste collection system and received a favorable determination by the International Searching Authority finding that all of the claims satisfy the requirements for novelty, inventive step and industrial applicability. Skyline anticipates that the favorable International Search Report will result in allowance of its various national applications.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one financial institution. The Company had a credit risk concentration as a result of depositing $4,621,764 of funds in excess of insurance limits in a single bank.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty Costs In 2015, the Company incurred approximately $56,201 in current warranty costs.
Segment Reporting, Policy [Policy Text Block]	Segments The Company operates in one segment for the sale of its medical device and consumable products. Substantially all of the Company’s assets, revenues, and expenses for 2015 and 2014 were located at or derived from operations in the United States. There were no revenues from sales outside of the United States.
Risks and Uncertainties, Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.

Note 1 - Summary of Significa21

Note 1 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of Inventory, Current [Table Text Block]	December 31, December 31, Finished goods $ 30,237 $ 88,362 Raw materials 162,623 237,556 Work-In-Process 38,880 41,449 Total $ 231,740 $ 367,367
Property, Plant and Equipment, Useful Life [Table Text Block]	Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3
Property, Plant and Equipment [Table Text Block]	December 31, December 31, Computers and office equipment $ 153,553 $ 123,708 Leasehold Improvements 23,874 23,874 Manufacturing Tooling 97,288 97,288 Demo Equipment 8,962 30,576 Total 283,677 275,446 Less: Accumulated Depreciation 144,079 78,967 Total Fixed Assets, Net $ 139,598 $ 196,479

Note 3 _ Stockholders_ Equity22

Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Tables)	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Activity [Table Text Block]	Stock Options Warrants Average Average Outstanding at December 31, 2013 385,733 $ 6.75 461,920 $ 10.50 Issued 75,683 8.12 161,375 3.81 Expired (7,879 ) 23.58 (81,851 ) 13.54 Exercised (4,936 ) 1.76 (40,722 ) 8.38 Outstanding at December 31, 2014 448,601 $ 7.51 500,722 $ 7.95 Issued 354,253 2.76 7,581,722 4.95 Cancelled (19,136 ) 11.73 (1,967 ) 11.34 Exercised - - (3,000 ) 4.95 Outstanding at December 31, 2015 783,718 $ 5.33 8,077,477 $ 5.14
Schedule of Share-based Compensation, Shares Authorized under Stock Option and Warrant Plans, by Exercise Price Range [Table Text Block]	Range of Exercise Prices Shares Weighted Options: $0.75 7,333 5.52 $2.63 250,481 9.81 $2.94 30,614 10.01 $3.10 59,681 9.50 $3.21 6,232 9.76 $3.45 7,245 9.25 $4.875 134 7.20 $5.25 2,031 6.69 $5.625 192,000 7.21 $5.925 23,206 7.22 $6.00 123,998 6.63 $6.50 3,845 9.01 $8.25 3,636 8.76 $9.9375 3,019 7.54 $10.50 3,238 7.54 $11.25 13,666 7.09 $12.75 67 7.36 $13.875 2,160 8.25 $71.25 40,261 8.19 $18.75 3,334 8.15 $20.25 4,940 8.01 $21.75 1,336 7.77 $23.85 1,260 7.75 Total 783,718 Warrants: $4.95 7,577,040 4.67 $6.00 102,857 2.20 $9.00 2,666 2.07 $9.75 63,227 3.59 $11.25 203,801 2.02 $12.375 71,257 3.61 $12.38 5,557 3.85 $13.50 4,444 2.47 $14.85 23,612 2.41 $20.25 1,481 3.13 $24.375 21,535 3.10 Total 8,077,477
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Year Shares Price 2011 11,666 .75 2012 126,029 5.25 – 6.00 2013 232,756 4.875 – 23.85 2014 59,013 6.50 – 18.75 2015 354,253 2.63 – 3.45 Total 783,718 $ .75 – 23.85 Year Shares Price 2012 69,801 11.25 – 15.00 2013 267,579 6.00 – 14.85 2014 161,375 12.375 – 24.375 2015 7,578,722 4.95 Total 8,077,477 $ 4.95 – 24.375

Note 5 - Loss Per Share (Tables

Note 5 - Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended 2015 2014 Numerator: Net loss available in basic and diluted calculation $ (4,790,530 ) $ (6,833,568 ) Denominator: Weighted average common shares outstanding-basic 3,880,828 2,990,471 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-diluted 3,880,828 2,990,471 Loss per common share-basic and diluted $ (1.23 ) $ (2.29 )

Note 6 - Income Taxes (Tables)

Note 6 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, December 31, Deferred Tax Asset: Net Operating Loss $ 10,338,000 $ 7,919,000 Other 359,000 1,150,000 Total Deferred Tax Asset 10,697,000 9,069,000 Less Valuation Allowance 10,697,000 9,069,000 Net Deferred Income Taxes $ — $ —

Note 7 _ Rent Obligation (Table

Note 7 – Rent Obligation (Tables)	12 Months Ended
	Dec. 31, 2015
Leases [Abstract]
Schedule of Rent Expense [Table Text Block]	2016 $ 38,000 2017 $ 39,000 2018 $ 3,000

Note 8 _ Liability for Equity26

Note 8 – Liability for Equity-Linked Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	Stock price $3.75 to $37.50 Exercise price $ .75 to $24.38 Expected life (years) 2.0 to 6.5 Expected volatility 59% Assumed dividend rate - % Risk-free interest rate .13% to 2.97%
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Initial Value Annual Gain (Loss) Value at 12/31/09 2010 Gain (Loss) Value at 12/31/10 2011 Gain (Loss) Value at 2012 Gain Value 2013 Gain Value 2014 Gain Value at January 1, 2009 adoption $ 479,910 $ (390,368 ) $ 870,278 $ 868,772 $ 1,506 $ (88,290 ) $ 89,796 $ (21,856 ) $ 111,652 $ 100,053 $ 11,599 $ 11,599 $ - Warrants issued in quarter ended 6/30/2009 169,854 20,847 149,007 147,403 1,604 (4,689 ) 6,293 6,293 - - - - - Warrants issued in quarter ended 9/30/2009 39,743 (738 ) 40,481 40,419 62 (1,562 ) 1,624 910 714 714 - - - Warrants is used in quarter ended 12/31/2009 12,698 617 12,081 12,053 28 (724 ) 752 415 337 337 - - - Subtotal 702,205 1,071,847 Warrants issued in quarter ended 3/31/2010 25,553 25,014 539 (5,570 ) 6,109 3,701 2,408 2,408 - - - Warrants issued in quarter ended 6/30/2010 31,332 30,740 592 (6,122 ) 6,714 6,083 631 631 - - - Warrants issued in quarter ended 9/30/2010 31,506 20,891 10,615 (44,160 ) 54,775 1,338 53,437 53,437 - - - Total $ 790,596 $ (369,642 ) $ 1,071,847 $ 1,145,292 $ 14,946 $ (151,117 ) $ 166,063 $ (3,116 ) $ 169,179 $ 157,580 $ 11,599 $ 11,599 $ -

Note 1 - Summary of Significa27

Note 1 - Summary of Significant Accounting Policies (Details)	12 Months Ended		168 Months Ended
	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)shares	Dec. 31, 2015USD ($)shares
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]
Common Stock, Shares, Outstanding (in Shares) | shares	5,206,428	3,092,766	5,206,428
Stockholders' Equity, Period Increase (Decrease)			$ 22,732,961
Stock Issued During Period, Value, New Issues	$ 13,060,880	$ 2,055,001
Debt Instrument, Increase (Decrease), Net			5,685,000
Advertising Expense	8,220	19,394
Research and Development Expense	261,000	394,000
Cash, Uninsured Amount	4,621,764		4,621,764
Product Warranty Expense	$ 56,201
Number of Operating Segments	1
IPO [Member]
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]
Stock Issued During Period, Value, New Issues			13,555,003
Non-US [Member]
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]
Revenues	$ 0	$ 0
Series A Convertible Preferred Stock [Member] | Private Placement [Member]
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]
Stock Issued During Period, Value, New Issues			$ 2,055,000
Earliest Tax Year [Member]
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]
Open Tax Year	2,012

Note 1 - Summary of Significa28

Note 1 - Summary of Significant Accounting Policies (Details) - Schedule of Inventory - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Schedule of Inventory [Abstract]
Finished goods	$ 30,237	$ 88,362
Raw materials	162,623	237,556
Work-In-Process	38,880	41,449
Total	$ 231,740	$ 367,367

Note 1 - Summary of Significa29

Note 1 - Summary of Significant Accounting Policies (Details) - Schedule of Property, Plant and Equipment, Useful Life	12 Months Ended
	Dec. 31, 2015
Leasehold Improvements [Member]
Note 1 - Summary of Significant Accounting Policies (Details) - Schedule of Property, Plant and Equipment, Useful Life [Line Items]
Property, plant, and equipment, useful life	5 years
Demo Equipment [Member]
Note 1 - Summary of Significant Accounting Policies (Details) - Schedule of Property, Plant and Equipment, Useful Life [Line Items]
Property, plant, and equipment, useful life	3 years
Minimum [Member] | Office Equipment [Member]
Note 1 - Summary of Significant Accounting Policies (Details) - Schedule of Property, Plant and Equipment, Useful Life [Line Items]
Property, plant, and equipment, useful life	3 years
Minimum [Member] | Manufacturing Tooling [Member]
Note 1 - Summary of Significant Accounting Policies (Details) - Schedule of Property, Plant and Equipment, Useful Life [Line Items]
Property, plant, and equipment, useful life	3 years
Maximum [Member] | Office Equipment [Member]
Note 1 - Summary of Significant Accounting Policies (Details) - Schedule of Property, Plant and Equipment, Useful Life [Line Items]
Property, plant, and equipment, useful life	7 years
Maximum [Member] | Manufacturing Tooling [Member]
Note 1 - Summary of Significant Accounting Policies (Details) - Schedule of Property, Plant and Equipment, Useful Life [Line Items]
Property, plant, and equipment, useful life	7 years

Note 1 - Summary of Significa30

Note 1 - Summary of Significant Accounting Policies (Details) - Schedule of Property, Plant and Equipment - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment Gross	$ 283,677	$ 275,446
Less: Accumulated Depreciation	144,079	78,967
Total Fixed Assets, Net	139,598	196,479
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment Gross	153,553	123,708
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment Gross	23,874	23,874
Manufacturing Tooling [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment Gross	97,288	97,288
Demo Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant, and Equipment Gross	$ 8,962	$ 30,576

Note 2 _ Development Stage Op31

Note 2 – Development Stage Operations (Details) - $ / shares	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2009
Note 2 – Development Stage Operations (Details) [Line Items]
Common Stock, Shares, Issued	5,206,428
Share Price			$ 26.25
Common Stock [Member]
Note 2 – Development Stage Operations (Details) [Line Items]
Share Price	$ 125.25

Note 3 _ Stockholders_ Equity32

Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details)	Mar. 11, 2016$ / sharesshares	Aug. 31, 2015USD ($)$ / sharesshares	Sep. 14, 2014	Jun. 30, 2014$ / sharesshares	Mar. 31, 2014$ / sharesshares	Feb. 04, 2014USD ($)$ / sharesshares	Jun. 30, 2015$ / sharesshares	Mar. 31, 2015$ / sharesshares	Jan. 31, 2015$ / sharesshares	Dec. 31, 2014$ / sharesshares	Nov. 30, 2014$ / sharesshares	Sep. 30, 2014$ / sharesshares	Aug. 31, 2014$ / sharesshares	Jun. 30, 2014$ / sharesshares	Mar. 31, 2014$ / sharesshares	Jan. 31, 2014USD ($)$ / shares	Mar. 31, 2014$ / sharesshares	Mar. 11, 2016$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2009$ / shares	Dec. 31, 2014$ / sharesshares	Jul. 24, 2015shares	Sep. 09, 2014$ / sharesshares	Jul. 31, 2014$ / sharesshares	Feb. 28, 2014$ / sharesshares
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share) | $ / shares		$ 9
Underwriter Price (in Dollars per share) | $ / shares		8.28
Underwriting Discount (in Dollars per share) | $ / shares		$ 0.72
Underwriting Commission		8.00%
Proceeds from Issuance or Sale of Equity (in Dollars) | $		$ 13,800,000
Option Granted to Underwriter to Purchase Additional Units, Period		45 days
Option Granted to Underwriter to Purchase Additional Units, Number of Units Granted		250,000
Option Granted to Underwriter to Purchase Additional Units, Additional Units Purchased		0
Underwriting Agreement, Non-accountable Expense Allowance, Percentage		1.00%
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares										$ 0.01	$ 0.01								$ 0.01	$ 0.01		$ 0.01
Warrant exercise price (in Dollars per share) | $ / shares					$ 11.25										$ 11.25		$ 11.25
Share Price (in Dollars per share) | $ / shares																					$ 26.25
Class of Warrant or Right, Outstanding																			8,077,477
Stock Issued During Period, Value, New Issues (in Dollars) | $																			$ 13,060,880	$ 2,055,001
Stock Issued During Period, Shares, New Issues											13,700
Cashless Exercise Of Common Stock Warrants Total															3,333
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																										21,538
Preferred Stock, Dividend Rate, Percentage				6.00%	6.00%
Conversion Of Stock Price Per Share (in Dollars per share) | $ / shares					$ 19.50
Stock Issued During Period, Shares, Preferred Stock Conversion				1,561	970
Number of Preferred Stock Shareholders				16	16									16	16		16
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period														3,725	4,444
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares				$ 19.50										$ 19.50
Percentage Reduction to Number of Warrants												11.00%													11.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																					1.37%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																			0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum																			59.00%	59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum																			66.00%	66.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																					2 years 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number																			780,718
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in Dollars per share) | $ / shares																			$ 5.29
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term																			8 years 62 days
Class of Warrant or Right, Number of Warrants Vested and Exercisable																			8,077,477
Allocated Share-based Compensation Expense (in Dollars) | $																			$ 871,877	$ 723,367
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars) | $																			$ 32,682
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition																			2 months
Common Stock, Shares Authorized										100,000,000									100,000,000	100,000,000		100,000,000	100,000,000
Preferred Stock, Shares Authorized																							20,000,000
Subsequent Event [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Share Price (in Dollars per share) | $ / shares	$ 0.18																	$ 0.18
Exchange Units [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Unit Purchase Option, Units Sold		1,666,667
Unit Purchase Option, Units Issued		228,343
Stock Issued During Period, Shares, Conversion of Convertible Securities		1,895,010
Corporate Stock Transfer, Inc. [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Unit Agreement, Number of Shares of Common Stock Included in Each Unit		1
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares		$ 0.01
Corporate Stock Transfer, Inc. [Member] | Exchange Units [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Unit Purchase Option, Units Issued		228,343
Unit Purchase Option, Number of Units Available for Underwriter to Purchase, Percentage		5.00%
Unit Purchase Option, Number of Units Available for Underwriter to Purchase		83,333
Unit Purchase Option, Exercise Price, Percentage		125.00%
Unit Purchase Option, Exercise Price (in Dollars per share) | $ / shares		$ 11.25
Common Stock [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Share Price (in Dollars per share) | $ / shares																			$ 125.25
Stock Issued During Period, Value, New Issues (in Dollars) | $																			$ 16,667
Stock Issued During Period, Shares, New Issues																			1,666,667
Stock Issued During Period, Shares, Preferred Stock Conversion																			228,343
Common Stock [Member] | Exchange Units [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		1,895,010
Warrant [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Cashless Exercise Of Common Stock Warrants Total																	15,442
Series A Warrants [Member] | Exchange Units [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		7,580,040
Series A Warrants [Member] | Corporate Stock Transfer, Inc. [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Unit Agreement, Number of Warrants Included in Each Unit		4
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Warrant exercise price (in Dollars per share) | $ / shares		$ 4.95
Cashless Exercise Formula, Definition of Letter "C" in the Formula, Closing Bid Price, Number of Trading Days Prior to the Time of Exercise		2
Cashless Exercise Formula, Closing Bid Price Per Share, Minimum to Be Used in the Formula (in Dollars per share) | $ / shares		$ 0.43
Beneficial Ownership Limitation, Percentage		4.99%
Class of Warrant or Right, Period Over Which Additional Adjustments to Price and Number of Shares May Be Made		3 years
Series A Warrants [Member] | Corporate Stock Transfer, Inc. [Member] | Subsequent Event [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	10.06																	10.06
Warrants Option to Settle in Cash, Fair Value Disclosure (in Dollars per share) | $ / shares	$ 4.3246																	$ 4.3246
Class of Warrant or Right, Exercised During Period																		3,390,935
Stock Issued During Period, Shares, Exercise Of Warrants																		34,053,653
Class of Warrant or Right, Outstanding	4,189,105																	4,189,105
Maximum [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Underwriting Agreement, Expenses Agreed to Reimburse the Underwriter (in Dollars) | $		$ 70,000
Warrant exercise price (in Dollars per share) | $ / shares																			$ 24.375
Share Price (in Dollars per share) | $ / shares										$ 37.50										$ 37.50		$ 37.50
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																			2.35%	2.75%		2.97%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																				10 years		6 years 6 months
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares																			$ 23.85	$ 13.9195
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term																			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $ / shares																			$ 5.5695
Minimum [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Warrant exercise price (in Dollars per share) | $ / shares																			$ 4.95
Share Price (in Dollars per share) | $ / shares										$ 3.75										$ 3.75		$ 3.75
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																			1.63%	1.44%		0.13%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																			5 years	5 years		2 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares																			$ 0.75	$ 3.2006
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $ / shares																			0.2750
Chief Executive Officer [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Stock Issued During Period, Value, Stock Options Exercised (in Dollars) | $																$ 4,336
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares																$ 1.25
Dr. Samuel Herschkowitz [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Warrant exercise price (in Dollars per share) | $ / shares																										$ 20.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																										1,482
Two Lenders [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Warrant exercise price (in Dollars per share) | $ / shares																									$ 12.38
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																									28,986
Purchasers [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities							3,121	3,121	3,122	1,559		1,561
Warrant exercise price (in Dollars per share) | $ / shares													$ 24.38
Class of Warrant or Right, Number of Securities Called by Warrants or Rights													61,539
Preferred Stock, Dividend Rate, Percentage							6.00%	6.00%		6.00%		6.00%
Conversion Of Stock Price Per Share (in Dollars per share) | $ / shares							$ 9.75	$ 9.75	$ 9.75
Number of Preferred Stock Shareholders							16	16	16	16		16								16		16
Maximum Number of Days Not Listed on Stock Market													180 days
Preferred Stock Conversion Price, Per Share (in Dollars per share) | $ / shares									$ 19.50	$ 19.50		$ 19.50
Four Lenders [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Warrant exercise price (in Dollars per share) | $ / shares												$ 12.38
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												37,440
Series B Convertible Preferred Stock [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Beneficial Ownership Limitation, Percentage		4.99%
Convertible Preferred Stock, Shares Issued upon Conversion		1
(in Dollars per share) | $ / shares										$ 0.01									$ 0.01	$ 0.01		$ 0.01
Preferred Stock, Shares Authorized										10,000,000									10,000,000	10,000,000		10,000,000
Series B Convertible Preferred Stock [Member] | Exchange Units [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		1,895,010
Series B Convertible Preferred Stock [Member] | Corporate Stock Transfer, Inc. [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Unit Agreement, Number of Shares of Preferred Stock Included in Each Unit		1
Series A Convertible Preferred Stock [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Warrant exercise price (in Dollars per share) | $ / shares																										$ 24.38
Stock Issued During Period, Value, New Issues (in Dollars) | $						$ 2,055,000
Stock Issued During Period, Shares, New Issues						20,550
Series A Convertible Preferred Stock [Member] | Exchange Units [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		84,770
Series A Convertible Preferred Stock [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
(in Dollars per share) | $ / shares						$ 0.01				$ 0.01									$ 0.01	$ 0.01		$ 0.01
(in Dollars per share) | $ / shares						$ 100				$ 100									$ 100	$ 100		$ 100
Preferred Stock, Shares Authorized										10,000,000									10,000,000	10,000,000		10,000,000
Scenario, All Outstanding Warrants Exercised at Minimum Bid Price [Member] | Series A Warrants [Member] | Corporate Stock Transfer, Inc. [Member] | Subsequent Event [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Stock Issued During Period, Shares, Exercise Of Warrants	42,130,704
The Convertible Notes [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Debt Instrument, Principal Redemption Amount (in Dollars) | $		$ 933,074
Debt Instrument, Redemption Premium, Percentage		40.00%
Debt Instrument, Redemption Price (in Dollars) | $		$ 1,548,792
Debt Instrument, Redemption Amount Paid To Affiliates (in Dollars) | $		$ 167,031
Equity Incentive Plan [Member] | Maximum [Member] | Employee, Director, and Consultant Stock Options [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																			3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																			10 years
Equity Incentive Plan [Member] | Minimum [Member] | Employee, Director, and Consultant Stock Options [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																			3 years
SOK Partners LLC [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) [Line Items]
Warrant exercise price (in Dollars per share) | $ / shares				$ 12.38										$ 12.38										$ 12.38
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				5,431										5,431										4,831
Percentage of Reduction to Warrant Agreement			11.00%

Note 3 _ Stockholders_ Equity33

Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Transactions for Stock Options and Warrants - $ / shares	1 Months Ended		12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Transactions for Stock Options and Warrants [Line Items]
Number of Shares Exercised	(3,725)	(4,444)
Number of Shares Outstanding			783,718
Average Exercise Price Outstanding
Warrant [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Transactions for Stock Options and Warrants [Line Items]
Number of Shares Outstanding			500,722	461,920
Average Exercise Price Outstanding			$ 7.95	$ 10.50
Number of Shares Issued			7,581,722	161,375
Average Exercise Price Issued			$ 4.95	$ 3.81
Number of Shares Expired			(1,967)	(81,851)
Average Exercise Price Expired			$ 11.34	$ 13.54
Number of Shares Exercised			(3,000)	(40,722)
Average Exercise Price Exercised			$ 4.95	$ 8.38
Number of Shares Outstanding			8,077,477	500,722
Average Exercise Price Outstanding			$ 5.14	$ 7.95
Employee Stock Option [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Transactions for Stock Options and Warrants [Line Items]
Number of Shares Outstanding			448,601	385,733
Average Exercise Price Outstanding			$ 7.51	$ 6.75
Number of Shares Issued			354,253	75,683
Average Exercise Price Issued			$ 2.76	$ 8.12
Number of Shares Expired			(19,136)	(7,879)
Average Exercise Price Expired			$ 11.73	$ 23.58
Number of Shares Exercised				(4,936)
Average Exercise Price Exercised				$ 1.76
Number of Shares Outstanding			783,718	448,601
Average Exercise Price Outstanding			$ 5.33	$ 7.51

Note 3 _ Stockholders_ Equity34

Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding - $ / shares	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2014
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options
Shares, Options (in Shares)	783,718
Range of Exercise Prices, Warrants		$ 11.25
Shares, Warrants (in Shares)	8,077,477
Stock Options One [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 0.75
Shares, Options (in Shares)	7,333
Weighted Average Remaining Life, Options	5 years 189 days
Stock Options Two [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 2.63
Shares, Options (in Shares)	250,481
Weighted Average Remaining Life, Options	9 years 295 days
Stock Options Three [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 2.94
Shares, Options (in Shares)	30,614
Weighted Average Remaining Life, Options	10 years 3 days
Stock Options Four [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 3.10
Shares, Options (in Shares)	59,681
Weighted Average Remaining Life, Options	9 years 6 months
Stock Options Five [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 3.21
Shares, Options (in Shares)	6,232
Weighted Average Remaining Life, Options	9 years 277 days
Stock Options Six [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 3.45
Shares, Options (in Shares)	7,245
Weighted Average Remaining Life, Options	9 years 3 months
Stock Options Seven [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 4.875
Shares, Options (in Shares)	134
Weighted Average Remaining Life, Options	7 years 73 days
Stock Options Eight [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 5.25
Shares, Options (in Shares)	2,031
Weighted Average Remaining Life, Options	6 years 251 days
Stock Options Nine [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 5.625
Shares, Options (in Shares)	192,000
Weighted Average Remaining Life, Options	7 years 76 days
Stock Option Ten [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 5.925
Shares, Options (in Shares)	23,206
Weighted Average Remaining Life, Options	7 years 80 days
Stock Option Eleven [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 6
Shares, Options (in Shares)	123,998
Weighted Average Remaining Life, Options	6 years 229 days
Stock Option Twelve [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 6.50
Shares, Options (in Shares)	3,845
Weighted Average Remaining Life, Options	9 years 3 days
Stock Options Thirteen [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 8.25
Shares, Options (in Shares)	3,636
Weighted Average Remaining Life, Options	8 years 277 days
Stock Options Fourteen [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 9.9375
Shares, Options (in Shares)	3,019
Weighted Average Remaining Life, Options	7 years 197 days
Stock Options Fifteen [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 10.50
Shares, Options (in Shares)	3,238
Weighted Average Remaining Life, Options	7 years 197 days
Stock Options Sixteen [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 11.25
Shares, Options (in Shares)	13,666
Weighted Average Remaining Life, Options	7 years 32 days
Stock Options Seventeen [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 12.75
Shares, Options (in Shares)	67
Weighted Average Remaining Life, Options	7 years 131 days
Stock Options Eighteen [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 13.875
Shares, Options (in Shares)	2,160
Weighted Average Remaining Life, Options	8 years 3 months
Stock Options Nineteen [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 71.25
Shares, Options (in Shares)	40,261
Weighted Average Remaining Life, Options	8 years 69 days
Stock Options Twenty [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 18.75
Shares, Options (in Shares)	3,334
Weighted Average Remaining Life, Options	8 years 54 days
Stock Options Twenty One [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 20.25
Shares, Options (in Shares)	4,940
Weighted Average Remaining Life, Options	8 years 3 days
Stock Options Twenty Two [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 21.75
Shares, Options (in Shares)	1,336
Weighted Average Remaining Life, Options	7 years 281 days
Stock Options Twenty Three [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Options	$ 23.85
Shares, Options (in Shares)	1,260
Weighted Average Remaining Life, Options	7 years 9 months
Warrant One [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Warrants	$ 4.95
Shares, Warrants (in Shares)	7,577,040
Weighted Average Remaining Life, Warrants	4 years 244 days
Warrant Two [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Warrants	$ 6
Shares, Warrants (in Shares)	102,857
Weighted Average Remaining Life, Warrants	2 years 73 days
Warrant Three [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Warrants	$ 9
Shares, Warrants (in Shares)	2,666
Weighted Average Remaining Life, Warrants	2 years 25 days
Warrant Four [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Warrants	$ 9.75
Shares, Warrants (in Shares)	63,227
Weighted Average Remaining Life, Warrants	3 years 215 days
Warrant Five [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Warrants	$ 11.25
Shares, Warrants (in Shares)	203,801
Weighted Average Remaining Life, Warrants	2 years 7 days
Warrant Six [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Warrants	$ 12.375
Shares, Warrants (in Shares)	71,257
Weighted Average Remaining Life, Warrants	3 years 222 days
Warrant Seven [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Warrants	$ 12.38
Shares, Warrants (in Shares)	5,557
Weighted Average Remaining Life, Warrants	3 years 310 days
Warrant Eight [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Warrants	$ 13.50
Shares, Warrants (in Shares)	4,444
Weighted Average Remaining Life, Warrants	2 years 171 days
Warrant Nine [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Warrants	$ 14.85
Shares, Warrants (in Shares)	23,612
Weighted Average Remaining Life, Warrants	2 years 149 days
Warrant Ten [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Warrants	$ 20.25
Shares, Warrants (in Shares)	1,481
Weighted Average Remaining Life, Warrants	3 years 47 days
Warrant Eleven [Member]
Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Summary of Status of Options and Warrants Outstanding [Line Items]
Range of Exercise Prices, Warrants	$ 24.375
Shares, Warrants (in Shares)	21,535
Weighted Average Remaining Life, Warrants	3 years 36 days

Note 3 _ Stockholders_ Equity35

Note 3 – Stockholders’ Equity (Deficit), Stock Options and Warrants (Details) - Schedule of Listing of Stock Options and Warrants - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Options (in Shares)	783,718
Shares, Warrants (in Shares)	8,077,477
Warrant exercise price (in Dollars per share)			$ 11.25
Stock Options 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Options (in Shares)	11,666
Price, Options	$ 0.75
Stock Options 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Options (in Shares)	126,029
Stock Options 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Options (in Shares)	232,756
Stock Options 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Options (in Shares)	59,013
Stock Options 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Options (in Shares)	354,253
Warrants 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Warrants (in Shares)	69,801
Warrants 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Warrants (in Shares)	267,579
Warrants 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Warrants (in Shares)	161,375
Warrants 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Warrants (in Shares)	7,578,722
Warrant exercise price (in Dollars per share)	$ 4.95
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price, Options	0.75	$ 3.2006
Warrant exercise price (in Dollars per share)	4.95
Minimum [Member] | Stock Options 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price, Options	5.25
Minimum [Member] | Stock Options 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price, Options	4.875
Minimum [Member] | Stock Options 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price, Options	6.50
Minimum [Member] | Stock Options 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price, Options	2.63
Minimum [Member] | Warrants 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant exercise price (in Dollars per share)	11.25
Minimum [Member] | Warrants 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant exercise price (in Dollars per share)	6
Minimum [Member] | Warrants 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant exercise price (in Dollars per share)	12.375
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price, Options	23.85	$ 13.9195
Warrant exercise price (in Dollars per share)	24.375
Maximum [Member] | Stock Options 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price, Options	6
Maximum [Member] | Stock Options 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price, Options	23.85
Maximum [Member] | Stock Options 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price, Options	18.75
Maximum [Member] | Stock Options 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price, Options	3.45
Maximum [Member] | Warrants 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant exercise price (in Dollars per share)	15
Maximum [Member] | Warrants 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant exercise price (in Dollars per share)	14.85
Maximum [Member] | Warrants 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant exercise price (in Dollars per share)	$ 24.375

Note 4 - Short-term Notes Pay36

Note 4 - Short-term Notes Payable (Details) - USD ($)	Aug. 31, 2015	May. 31, 2015	Sep. 30, 2014	Dec. 31, 2015	Jun. 30, 2015	Sep. 09, 2014	Jul. 31, 2014	Jun. 30, 2014	Feb. 28, 2014
Note 4 - Short-term Notes Payable (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)									21,538
Percentage Reduction to Number of Warrants			11.00%				11.00%
The 2014 Convertible Notes [Member]
Note 4 - Short-term Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount			$ 1,800,000
DebtInstrumentReducedFaceAmount			1,600,000			$ 1,603,260
Proceeds from Convertible Debt			1,475,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)						71,257
Percentage Reduction to Debt Instrument, Face Amount						11.00%
Percentage Reduction to Number of Warrants						11.00%
The 2015 Convertible Notes [Member]
Note 4 - Short-term Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount		$ 275,000
Proceeds from Convertible Debt		$ 250,000
Class of Warrant or Right, Issued During Period (in Shares)		0
The Convertible Notes [Member]
Note 4 - Short-term Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount					$ 933,073
Debt Conversion, Converted Instrument, Amount					$ 927,663
Debt Instrument, Redemption Price, Percentage				140.00%
Debt Instrument, Principal Redemption Amount	$ 933,074
Debt Instrument, Redemption Premium, Percentage	40.00%
Debt Instrument, Redemption Price	$ 1,548,792
Debt Instrument, Redemption Amount Paid To Affiliates	$ 167,031
Short-term Debt				$ 0
SOK Partners LLC [Member]
Note 4 - Short-term Notes Payable (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)						4,831		5,431
SOK Partners LLC [Member] | The 2014 Convertible Notes [Member]
Note 4 - Short-term Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount			122,196
Proceeds from Convertible Debt			$ 100,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)			5,431

Note 5 - Loss Per Share (Detail

Note 5 - Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Options and Warrants [Member]
Note 5 - Loss Per Share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	8,861,195	949,323
Preferred Stock 1 [Member]
Note 5 - Loss Per Share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,898,010

Note 5 - Loss Per Share (Deta38

Note 5 - Loss Per Share (Details) - Shares Used in Basic and Diluted Loss Per Common Share Computations - USD ($)		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
Numerator:
Net loss available in basic and diluted calculation (in Dollars)		$ (4,790,530)	$ (6,833,568)
Denominator:
Weighted average common shares outstanding-basic		3,880,828	2,990,471
Effect of dilutive stock options, warrants and preferred stock (1)	[1]
Weighted average common shares outstanding-diluted		3,880,828	2,990,471
Loss per common share-basic and diluted (in Dollars per share)		$ (1.23)	$ (2.29)
[1]	The number of shares underlying options and warrants outstanding as of December 31, 2015 and December 31, 2014 are 8,861,195 and 949,323, respectively. The number of shares underlying the preferred stock as of December 31, 2015 is 1,898,010. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculationof diluted loss per share because those shares are anti-dilutive.

Note 6 - Income Taxes (Details)

Note 6 - Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Note 6 - Income Taxes (Details) [Line Items]
Income Tax Expense (Benefit)	$ 0
Valuation Allowance Percentage	100.00%
Domestic Tax Authority [Member]
Note 6 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	$ 24,700,000	$ 18,700,000
Operating Loss Carryforwards, Valuation Allowance	9,600,000	8,100,000
State and Local Jurisdiction [Member]
Note 6 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	13,400,000	12,400,000
Operating Loss Carryforwards, Valuation Allowance	$ 1,100,000	$ 1,000,000

Note 6 - Income Taxes (Detail40

Note 6 - Income Taxes (Details) - Components of Deferred Income Taxes - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred Tax Asset:
Net Operating Loss	$ 10,338,000	$ 7,919,000
Other	359,000	1,150,000
Total Deferred Tax Asset	10,697,000	9,069,000
Less Valuation Allowance	10,697,000	9,069,000
Net Deferred Income Taxes	$ 0	$ 0

Note 7 _ Rent Obligation (Detai

Note 7 – Rent Obligation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Leases [Abstract]
Lessee Leasing Arrangements, Operating Leases, Terms of Contract Cancellation	3 years
Lessee Leasing Arrangements, Operating Leases, Extension Term	5 years
Operating Leases, Rent Expense (in Dollars)	$ 66,345	$ 64,753
Lessor Leasing Arrangements, Operating Leases, Term of Contract	3 years

Note 7 _ Rent Obligation (Det42

Note 7 – Rent Obligation (Details) - Rent Obligation	Dec. 31, 2015USD ($)
Rent Obligation [Abstract]
2,016	$ 38,000
2,017	39,000
2,018	$ 3,000

Note 8 _ Liability for Equity43

Note 8 – Liability for Equity-Linked Financial Instruments (Details) - USD ($)	12 Months Ended			72 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2009	Dec. 31, 2014	Dec. 31, 2010
Note 8 – Liability for Equity-Linked Financial Instruments (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term			2 years 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate			63.00%	59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price (in Dollars per share)			$ 34.50
Share Price (in Dollars per share)			$ 26.25
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			1.37%
Share Price Reduction			$ 37.50		$ 16.50
Decrease In Equity Caused By Adoption of ASC 815 [Member]
Note 8 – Liability for Equity-Linked Financial Instruments (Details) [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification			479,910
Decrease In Additional Paid In Capital Caused By Adoption Of ASC 815 [Member]
Note 8 – Liability for Equity-Linked Financial Instruments (Details) [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification			486,564
Increase In Retained Earnings Caused By Adoption Of ASC 815 [Member]
Note 8 – Liability for Equity-Linked Financial Instruments (Details) [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification			6,654
Increase In Liabilities Caused By Adoption Of ASC 815 [Member]
Note 8 – Liability for Equity-Linked Financial Instruments (Details) [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification			$ 479,910
Derivative Liability		$ 0		$ 0

Note 8 _ Liability for Equity44

Note 8 – Liability for Equity-Linked Financial Instruments (Details) - Inputs to Black-Scholes Model - $ / shares	12 Months Ended			72 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2009	Dec. 31, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price			$ 26.25
Exercise price			$ 34.50
Expected life (years)			2 years 6 months
Expected volatility			63.00%	59.00%
Risk-free interest rate			1.37%
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price		$ 3.75		$ 3.75
Exercise price		$ 0.75		$ 0.75
Expected life (years)	5 years	5 years		2 years
Risk-free interest rate	1.63%	1.44%		0.13%
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price		$ 37.50		$ 37.50
Exercise price		$ 24.38		$ 24.38
Expected life (years)		10 years		6 years 6 months
Risk-free interest rate	2.35%	2.75%		2.97%

Note 8 _ Liability for Equity45

Note 8 – Liability for Equity-Linked Financial Instruments (Details) - Original Valuations, Annual Gain (Loss) and End of Year Valuations - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Class of Warrant or Right [Line Items]
Total							$ 790,596
Gain Loss 2009 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)						$ (369,642)
Total						(369,642)
Value At 2009 [Member]
Class of Warrant or Right [Line Items]
Total						1,071,847
Gain Loss 2010 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)					$ 1,145,292
Total					1,145,292
Value At 2010 [Member]
Class of Warrant or Right [Line Items]
Total					14,946
Gain Loss 2011 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)				$ (151,117)
Total				(151,117)
Value At 2011 [Member]
Class of Warrant or Right [Line Items]
Total				166,063
Gain Loss 2012 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)			$ (3,116)
Total			(3,116)
Value At 2012 [Member]
Class of Warrant or Right [Line Items]
Total			169,179
Gain Loss 2013 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)		$ 157,580
Total		157,580
Value At 2013 [Member]
Class of Warrant or Right [Line Items]
Total		11,599
Gain Loss 2014 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)	$ 11,599
Total	11,599
January 1, 2009 Adoption [Member]
Class of Warrant or Right [Line Items]
Value							479,910
January 1, 2009 Adoption [Member] | Gain Loss 2009 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)						(390,368)
Total						(390,368)
January 1, 2009 Adoption [Member] | Value At 2009 [Member]
Class of Warrant or Right [Line Items]
Value						870,278
January 1, 2009 Adoption [Member] | Gain Loss 2010 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)					868,772
Total					868,772
January 1, 2009 Adoption [Member] | Value At 2010 [Member]
Class of Warrant or Right [Line Items]
Value					1,506
January 1, 2009 Adoption [Member] | Gain Loss 2011 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)				(88,290)
Total				(88,290)
January 1, 2009 Adoption [Member] | Value At 2011 [Member]
Class of Warrant or Right [Line Items]
Value				89,796
January 1, 2009 Adoption [Member] | Gain Loss 2012 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)			(21,856)
Total			(21,856)
January 1, 2009 Adoption [Member] | Value At 2012 [Member]
Class of Warrant or Right [Line Items]
Value			111,652
January 1, 2009 Adoption [Member] | Gain Loss 2013 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)		100,053
Total		100,053
January 1, 2009 Adoption [Member] | Value At 2013 [Member]
Class of Warrant or Right [Line Items]
Value		11,599
January 1, 2009 Adoption [Member] | Gain Loss 2014 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)	11,599
Total	$ 11,599
Issued in Quarter Ended 6/30/2009 [Member]
Class of Warrant or Right [Line Items]
Value							169,854
Issued in Quarter Ended 6/30/2009 [Member] | Gain Loss 2009 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)						20,847
Total						20,847
Issued in Quarter Ended 6/30/2009 [Member] | Value At 2009 [Member]
Class of Warrant or Right [Line Items]
Value						149,007
Issued in Quarter Ended 6/30/2009 [Member] | Gain Loss 2010 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)					147,403
Total					147,403
Issued in Quarter Ended 6/30/2009 [Member] | Value At 2010 [Member]
Class of Warrant or Right [Line Items]
Value					1,604
Issued in Quarter Ended 6/30/2009 [Member] | Gain Loss 2011 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)				(4,689)
Total				(4,689)
Issued in Quarter Ended 6/30/2009 [Member] | Value At 2011 [Member]
Class of Warrant or Right [Line Items]
Value				6,293
Issued in Quarter Ended 6/30/2009 [Member] | Gain Loss 2012 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)			6,293
Total			6,293
Warrants Issued in Quarter Ended 9/30/2009 [Member]
Class of Warrant or Right [Line Items]
Value							39,743
Warrants Issued in Quarter Ended 9/30/2009 [Member] | Gain Loss 2009 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)						(738)
Total						(738)
Warrants Issued in Quarter Ended 9/30/2009 [Member] | Value At 2009 [Member]
Class of Warrant or Right [Line Items]
Value						40,481
Warrants Issued in Quarter Ended 9/30/2009 [Member] | Gain Loss 2010 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)					40,419
Total					40,419
Warrants Issued in Quarter Ended 9/30/2009 [Member] | Value At 2010 [Member]
Class of Warrant or Right [Line Items]
Value					62
Warrants Issued in Quarter Ended 9/30/2009 [Member] | Gain Loss 2011 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)				(1,562)
Total				(1,562)
Warrants Issued in Quarter Ended 9/30/2009 [Member] | Value At 2011 [Member]
Class of Warrant or Right [Line Items]
Value				1,624
Warrants Issued in Quarter Ended 9/30/2009 [Member] | Gain Loss 2012 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)			910
Total			910
Warrants Issued in Quarter Ended 9/30/2009 [Member] | Value At 2012 [Member]
Class of Warrant or Right [Line Items]
Value			714
Warrants Issued in Quarter Ended 9/30/2009 [Member] | Gain Loss 2013 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)		714
Total		714
Issued in Quarter Ended 12/31/2009 [Member]
Class of Warrant or Right [Line Items]
Value							12,698
Issued in Quarter Ended 12/31/2009 [Member] | Gain Loss 2009 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)						617
Total						617
Issued in Quarter Ended 12/31/2009 [Member] | Value At 2009 [Member]
Class of Warrant or Right [Line Items]
Value						12,081
Issued in Quarter Ended 12/31/2009 [Member] | Gain Loss 2010 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)					12,053
Total					12,053
Issued in Quarter Ended 12/31/2009 [Member] | Value At 2010 [Member]
Class of Warrant or Right [Line Items]
Value					28
Issued in Quarter Ended 12/31/2009 [Member] | Gain Loss 2011 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)				(724)
Total				(724)
Issued in Quarter Ended 12/31/2009 [Member] | Value At 2011 [Member]
Class of Warrant or Right [Line Items]
Value				752
Issued in Quarter Ended 12/31/2009 [Member] | Gain Loss 2012 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)			415
Total			415
Issued in Quarter Ended 12/31/2009 [Member] | Value At 2012 [Member]
Class of Warrant or Right [Line Items]
Value			337
Issued in Quarter Ended 12/31/2009 [Member] | Gain Loss 2013 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)		337
Total		337
Issued in 2009 and January 1, 2009 Adoption [Member]
Class of Warrant or Right [Line Items]
Value							702,205
Issued in 2009 and January 1, 2009 Adoption [Member] | Value At 2009 [Member]
Class of Warrant or Right [Line Items]
Value						$ 1,071,847
Issued in Quarter Ended 3/31/2010 [Member]
Class of Warrant or Right [Line Items]
Value							25,553
Issued in Quarter Ended 3/31/2010 [Member] | Gain Loss 2010 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)					25,014
Total					25,014
Issued in Quarter Ended 3/31/2010 [Member] | Value At 2010 [Member]
Class of Warrant or Right [Line Items]
Value					539
Issued in Quarter Ended 3/31/2010 [Member] | Gain Loss 2011 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)				(5,570)
Total				(5,570)
Issued in Quarter Ended 3/31/2010 [Member] | Value At 2011 [Member]
Class of Warrant or Right [Line Items]
Value				6,109
Issued in Quarter Ended 3/31/2010 [Member] | Gain Loss 2012 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)			3,701
Total			3,701
Issued in Quarter Ended 3/31/2010 [Member] | Value At 2012 [Member]
Class of Warrant or Right [Line Items]
Value			2,408
Issued in Quarter Ended 3/31/2010 [Member] | Gain Loss 2013 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)		2,408
Total		2,408
Issued in Quarter Ended 6/30/2010 [Member]
Class of Warrant or Right [Line Items]
Value							31,332
Issued in Quarter Ended 6/30/2010 [Member] | Gain Loss 2010 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)					30,740
Total					30,740
Issued in Quarter Ended 6/30/2010 [Member] | Value At 2010 [Member]
Class of Warrant or Right [Line Items]
Value					592
Issued in Quarter Ended 6/30/2010 [Member] | Gain Loss 2011 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)				(6,122)
Total				(6,122)
Issued in Quarter Ended 6/30/2010 [Member] | Value At 2011 [Member]
Class of Warrant or Right [Line Items]
Value				6,714
Issued in Quarter Ended 6/30/2010 [Member] | Gain Loss 2012 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)			6,083
Total			6,083
Issued in Quarter Ended 6/30/2010 [Member] | Value At 2012 [Member]
Class of Warrant or Right [Line Items]
Value			631
Issued in Quarter Ended 6/30/2010 [Member] | Gain Loss 2013 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)		631
Total		631
Issued in Quarter Ended 9/30/2010 [Member]
Class of Warrant or Right [Line Items]
Value							$ 31,506
Issued in Quarter Ended 9/30/2010 [Member] | Gain Loss 2010 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)					20,891
Total					20,891
Issued in Quarter Ended 9/30/2010 [Member] | Value At 2010 [Member]
Class of Warrant or Right [Line Items]
Value					$ 10,615
Issued in Quarter Ended 9/30/2010 [Member] | Gain Loss 2011 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)				(44,160)
Total				(44,160)
Issued in Quarter Ended 9/30/2010 [Member] | Value At 2011 [Member]
Class of Warrant or Right [Line Items]
Value				$ 54,775
Issued in Quarter Ended 9/30/2010 [Member] | Gain Loss 2012 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)			1,338
Total			1,338
Issued in Quarter Ended 9/30/2010 [Member] | Value At 2012 [Member]
Class of Warrant or Right [Line Items]
Value			$ 53,437
Issued in Quarter Ended 9/30/2010 [Member] | Gain Loss 2013 [Member]
Class of Warrant or Right [Line Items]
Gain (Loss)		53,437
Total		$ 53,437

Note 9 - Related Pary Transac46

Note 9 - Related Pary Transactions (Details) - USD ($)	Aug. 31, 2015	Feb. 04, 2014	Aug. 31, 2015	Nov. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Jul. 31, 2014	Feb. 28, 2014
Note 9 - Related Pary Transactions (Details) [Line Items]
Stock Issued During Period, Shares, New Issues				13,700
Stock Issued During Period, Value, New Issues (in Dollars)					$ 13,060,880	$ 2,055,001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								21,538
Common Stock [Member]
Note 9 - Related Pary Transactions (Details) [Line Items]
Stock Issued During Period, Shares, New Issues					1,666,667
Stock Issued During Period, Value, New Issues (in Dollars)					$ 16,667
Chief Executive Officer [Member] | Stock Conversion from Series A Convertible Stock to Exchange Units [Member]
Note 9 - Related Pary Transactions (Details) [Line Items]
Conversion of Stock, Shares Converted	250
Conversion of Stock, Shares Issued	2,778
Chief Executive Officer [Member] | Common Stock [Member]
Note 9 - Related Pary Transactions (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		52
Chief Executive Officer [Member] | Series A Preferred Stock [Member]
Note 9 - Related Pary Transactions (Details) [Line Items]
Stock Issued During Period, Shares, New Issues		19,231
Stock Issued During Period, Value, New Issues (in Dollars)		$ 25,000
SOK Partners LLC [Member]
Note 9 - Related Pary Transactions (Details) [Line Items]
Ownership Percentage							10.00%
SOK Partners LLC [Member] | Convertible Notes [Member]
Note 9 - Related Pary Transactions (Details) [Line Items]
Debt Instrument, Redemption Price, Percentage			140.00%
Repayments of Related Party Debt (in Dollars)			$ 163,000

Note 10 - Retirement Savings 47

Note 10 - Retirement Savings Plans (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%	100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	4.00%	4.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount (in Dollars)	$ 39,916	$ 37,730

Note 11 - Supplemental Cash F48

Note 11 - Supplemental Cash Flow Data (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Interest Paid	$ 246,620	$ 47,111

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details)	1 Months Ended
	Jan. 31, 2016shares
Subsequent Event [Member]
Note 12 - Subsequent Events (Details) [Line Items]
Units Exchanged During Period	1,895,010